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aa   aminoacids 
ADAM  a disintegrin and metalloproteinase 
ANOVA  analysis of variance 
APES   3-aminopropyltriethoxysilane 
AREG   amphiregulin 
BFR   bone formation rate 
BMD   bone mineral density 
bp   base pair 
B.Pm   bone perimeter 
BS   bone surface 
BTC   betacellulin 
BV   bone volume 
COL1   collagen α1 promoter 
Cre   causes recombination 
Crea   creatinine 
Ct.Ar   cortical area 
CTF   cytosolic fragment 
Ct.Th   cortical thickness 
DPD   deoxypyridinoline 
Dsk5   dark skin 5 
E   embryonic day 
Ec.BPm  endocortical bone perimeter 
EDTA   ethylenediaminetetraacetate 
e.g.   exempli gratia 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
EGR   early growth response 
EIA   enzyme immunoassay 
ELISA   enzyme-linked immunosorbent assay 
EPGN   epigen 
EREG   epiregulin 
 FELASA Federation of European Laboratory Animal Science Associations 
GH   growth hormone, somatotropin 
GMCSF  granulocyte-macrophage colony-stimulating factor 
G-protein  guanine nucleotide-binding protein 
GRB2   growth factor receptor-bound protein 2 
h   hour / hours 
HBEGF  heparin-binding EGF-like growth factor 
HoleAr  hole area 
HoleNo  hole number 
HolePm  hole perimeter 
IGF1   insulin-like growth factor 1 
IL   interleukin 
KO   knockout 
L1   first lumbar vertebra 
loxP   locus of crossing-over 
Ma.Ar   marrow area 
MAPK   mitogen-activated protein kinase 
MAR   mineral apposition rate 
MCF   Michigan Cancer Foundation 
MCP1   monocyte chemoattractant protein 1 
MCSF   macrophage colony-stimulating factor 
min   minute / minutes 
MMA   methylmethacrylate 
MMP   matrix metalloproteinase 
MMRRC  The Mutant Mouse Regional Resource Center 
mRNA  messenger ribonucleic acid 
NF-κb   nuclear factor-kappa b 
N.Oc   number of osteoclasts 
N.Tb   number of trabeculae 
Ob.S   osteoblast surface 
O.Th   osteoid thickness 
OV   osteoid volume 
PBS   phosphate buffered saline 
PCR   Polymerase chain reaction 
 PI3K   phosphatidylinositol 3’kinase 
PKA   protein kinase A 
PKC   protein kinase C 
PLC   phospholipase C 
pQCT   Peripheral quantitative computed tomography 
Pro-AREG  “pro-form” of amphiregulin, amphiregulin precursor 
Ps.BPm  periosteal bone perimeter 
PTH   parathyroid hormone 
PTHrP  parathyroid hormone related peptide 
RANK   receptor activator of nuclear factor-kappa b 
RANKL  receptor activator of nuclear factor-kappa b ligand 
RUNX2  Runt-related transcription factor 2 
Scid   severe combined immunodeficiency 
SEM   standard error of the mean 
SH2   Src-homology-2 
siRNA   small interfering ribonucleic acid 
SNK test  Student-Newman-Keuls test 
SOS   son of sevenless 
STAT   signal transducer and activator of transcription 
TACE   tumor-necrosis factor alpha converting enzyme 
TAE buffer  Tris-acetate-EDTA-buffer 
T.Ar   tissue area 
Tb.Ar   trabecular area 
Tb.N   trabecular number 
Tb.Sp   trabecular separation 
Tb.Wi   trabecular width 
TGFA   transforming growth factor alpha 
TRAP   tartrate-resistant acid phosphatase 
TRIS   Tris(hydroxymethyl)aminomethane 
Tt.Ar   total area 
TtCross-sectAr total cross-sectional area 
TV   tissue volume 
Wa5   waved 5 
WT   wild-type control  
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1 Introduction 
 
The bone is a complex organ that fulfils a great variety of functions including mechan-
ical support, protection of vital organs, regulation of blood calcium levels and hemato-
poiesis sustenance. To perform these multiple functions, bone tissue is constantly re-
modeled in a cyclical renewal process, where bone resorption by osteoclasts is con-
tinuously counterbalanced by osteoblastic bone formation (Schneider et al., 2009b). 
Parathyroid hormone (PTH) is a major endocrine regulator of bone remodeling and 
calcium homeostasis (Poole and Reeve, 2005, Schneider et al., 2009b). It is secreted 
by the parathyroid glands in response to low extracellular calcium levels and, after 
binding to the PTH-receptor on its target cells, it activates several signaling cascades 
(Poole and Reeve, 2005, Swarthout et al., 2002). PTH raises the reduced blood cal-
cium levels by stimulating bone resorption, tubular calcium re-absorption in the kidney 
and synthesis of 1,25-dihydroxyvitamin D3, thus increasing the calcium uptake in the 
small intestine. In addition to this classical bone catabolic action, PTH can also act as 
a bone anabolic agent and significantly increase the bone mineral density (BMD) when 
administered intermittently (Hock et al., 1988, Poole and Reeve, 2005, Tam et al., 
1982).  
Although many signaling pathways and molecules have been identified to be key fac-
tors in mediating the bone anabolic effect of intermittent PTH, the detailed mechanisms 
have not yet been fully understood. There is accumulating evidence that amphiregulin 
(AREG), one ligand of the epidermal growth factor receptor (EGFR), is involved in me-
diating the bone anabolic effect of intermittent PTH (Schneider et al., 2009b, Schneider 
and Wolf, 2009). 
Areg is significantly upregulated in osteoblastic cells and bone tissue after PTH treat-
ment and was therefore identified as a PTH-regulated target gene both in vivo and in 
vitro (Qin et al., 2005). Expression of Areg can also be modulated by other osteotropic 
hormones, such as 1,25-dihydroxyvitamin D3 and prostaglandin E2 (Qin et al., 2005). 
Furthermore, release of AREG by osteoblastic cells after PTH treatment increases the 
recruitment of bone marrow mesenchymal progenitors via PI3K/Akt and p38MAPK 
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pathways and subsequently promotes their migration towards the bone surface (Zhu 
et al., 2012). The bone anabolic effect of intermittent PTH was blunted in osteoblast-
specific EGFR-knockout mice (Zhu et al., 2012). Moreover, female mice lacking AREG 
have less trabecular bone as compared to their controls (Qin et al., 2005). Vice versa, 
mice overexpressing Areg specifically in osteoblasts revealed a transient increase in 
trabecular bone mass (Vaidya et al., 2015). Hence, these data indicate that AREG 
seems to be the main EGFR ligand mediating the bone anabolic effect of PTH. 
To clarify to which extent AREG is required for the bone anabolic actions of PTH, we 
treated AREG deficient and control female mice at an age of 12 weeks intermittently 
with PTH or vehicle (physiological saline) for four weeks and examined their bone phe-
notype in detail. 
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2 Review of literature 
 
Epidermal growth factor receptor 
The epidermal growth factor receptor (EGFR, HER1, ERBB1) is a transmembrane ty-
rosine kinase receptor that can be activated by seven ligands: amphiregulin (AREG) 
(Berasain and Avila, 2014), betacellulin (BTC) (Dahlhoff et al., 2014), epidermal growth 
factor (EGF) (Zeng and Harris, 2014), epigen (EPGN) (Schneider and Yarden, 2013), 
epiregulin (EREG) (Riese and Cullum, 2014), heparin-binding EGF-like growth factor 
(HBEGF) (Taylor et al., 2014) and transforming growth factor α (TGFA) (Singh and 
Coffey, 2014). Once bound by a ligand, the EGFR forms homodimers with another 
EGFR molecule or heterodimers with one of the closely related receptors ERBB2 
(HER2, NEU), ERBB3 (HER3) or ERBB4 (HER4) (Citri and Yarden, 2006). In addition, 
the EGFR can be transactivated via other receptors, such as G-protein-coupled recep-
tors (also known as seven transmembrane-domain receptors), whose activation lead 
to cleavage of the membrane-bound ligand precursors (Yarden and Sliwkowski, 2001, 
Prenzel et al., 1999, Tao and Conn, 2014). The ligands of the four ERBB receptors 
can be divided into three groups: The first group binds exclusively to the EGFR and 
includes AREG, EGF, EPGN and TGFA. The second group includes BTC, EREG and 
HBEGF and binds both the EGFR and ERBB4. The neuregulins (NRG1 – NRG4) are 
representing the third group. NRG1 and NRG2 bind both ERBB3 and ERBB4, whereas 
NRG3 and NRG4 only bind to ERBB4 (Arteaga and Engelman, 2014). ERBB2 has no 
known ligand, but it is the preferred dimerization partner of the other ERBB receptors, 
and is able to amplify their signaling (Citri and Yarden, 2006, Yarden and Sliwkowski, 
2001). 
Phosphorylation of the receptor dimers on specific tyrosine residues of the intracellular 
tails leads to the recruitment of a number of signal transducers, such as the Src-ho-
mology-2 (SH2) and growth factor receptor-bound protein 2 (GRB2), which initiate the 
recruitment of RAS and the activation of mitogen-activated protein kinase (MAPK) 
pathways. Other important pathways are the phosphatidylinositol 3’kinase (PI3K-AKT) 
pathway, the phospholipase Cγ-protein kinase C (PLC-PKC) pathway and the signal 
transducer and activator of transcription (STAT) 1, 3 and 5 (Citri and Yarden, 2006, 
Schneider et al., 2009b, Yarden and Sliwkowski, 2001). 
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Most mice lacking EGFR die at mid-gestation or birth, but they may survive up to post-
natal day 20 depending on their genetic background. Surviving EGFR-Knockout mice 
are growth retarded, have an impaired epithelial development and show abnormalities 
in several organs, including skin, kidney, brain and bone (Citri and Yarden, 2006, 
Miettinen et al., 1995, Sibilia and Wagner, 1995, Threadgill et al., 1995).  
Egfr overexpression has been described in several tumor types, e.g. in lung and pan-
creas, and EGFR inhibitors, such as the monoclonal antibody cetuximab, are used 
successfully in cancer therapy (Citri and Yarden, 2006, Arteaga and Engelman, 2014). 
 
 
 
Figure 1 Simplified schematic overview of the binding specificities of the ERBB receptor ligands. AREG, 
EGF, EPGN and TGFA specifically bind to EGFR, whereas BTC, EREG and HBEGF bind both EGFR 
and ERBB4. ERBB2 has no known ligand. NRG1 and NRG2 bind both ERBB3 and ERBB4, whereas 
NRG3 and NRG4 only bind to ERBB4. 
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Amphiregulin 
AREG was first identified in the serum-free conditioned medium of MCF-7 human 
breast carcinoma cells treated with phorbol 12-myristate 13-acetate (Shoyab et al., 
1988). AREG was described as a bifunctional growth factor, with the ability to inhibit 
the growth of several human carcinoma cells and at the same time to stimulate the 
growth of human fibroblasts and other cells (Shoyab et al., 1988, Berasain and Avila, 
2014), a capacity which led to its name. Today AREG is known as one ligand of the 
EGFR and is therefore mainly involved in regulating cell proliferation and differentiation 
(Schneider and Wolf, 2009, Harris et al., 2003). 
Areg is expressed as a type I transmembrane glycoprotein precursor (Pro-AREG) of 
252 aminoacids (Fitch et al., 2003). The soluble form of AREG (78-84 aa) is formed 
via proteolytic cleavage of Pro-AREG by the membrane-bound tumor necrosis factor 
alpha converting enzyme (TACE), which belongs to the disintegrin and metalloprotein-
ase family (ADAM17) (Berasain et al., 2007, Harris et al., 2003, Hinkle et al., 2004, 
Sahin et al., 2004, Sunnarborg et al., 2002). Mature AREG contains the EGF motif and 
can activate the EGFR in a paracrine or autocrine manner, but the EGFR can also be 
activated by Pro-AREG via juxtacrine interactions or via exosomes expressing Pro-
AREG (Higginbotham et al., 2011, Singh and Harris, 2005, Willmarth and Ethier, 2006). 
Additionally, it was shown that Pro-AREG and the AREG-cytosolic fragment (AREG-
CTF) generated after AREG cleavage can be internalized into the nucleus and may be 
responsible for part of AREG effects (Berasain and Avila, 2014, Isokane et al., 2008). 
Areg is expressed in many tissues, including lung, heart, spleen, kidney, pancreas, 
colon, testis, placenta, ovary and breast (Plowman et al., 1990). Recently, AREG was 
found in human colostrum (Nojiri et al., 2012).  
6 
 
Figure 2 Schematic overview of AREG processing and signaling. TACE-mediated proteolytic cleavage 
of Pro-AREG leads to the soluble form of AREG, which can activate the EGFR via autocrine (A) or 
paracrine (B) signaling. C Exosomes expressing Pro-AREG can activate the EGFR via paracrine sig-
naling. D Pro-AREG and the AREG cytosolic fragment (AREG-CTF) can also, at least in part, mediate 
AREG effects via intracellular signaling. E Membrane-bound Pro-AREG can bind the EGFR of neigh-
boring cells and therefore signal via juxtacrine interactions.
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Mice lacking AREG are viable and fertile, but show an impaired mammary gland de-
velopment (Luetteke et al., 1999), develop mucosal lesions in the fundus of the stom-
ach (Nam et al., 2009) and, although Areg expression in the healthy liver is very low, 
show signs of liver damage (Berasain et al., 2005). It is reported that AREG-KO mice 
have less trabecular bone as compared to their control littermates (Qin et al., 2005). 
Mice overexpressing Areg in basal keratinocytes show a psoriasis-like phenotype 
(Cook et al., 1997), and most recently it was demonstrated that osteoblast-specific 
Areg overexpression leads to a transient anabolic effect in long bones (Vaidya et al., 
2015). 
Areg is overexpressed in several cancer types, e.g. breast, lung, liver, stomach, pan-
creas and colon. AREG has intrinsic tumor-promoting activities and can stimulate cel-
lular invasion and increase cell motility (Busser et al., 2011). Most recently it was 
shown that increased Areg expression promotes migration of human osteosarcoma 
cell lines in vitro and cell metastasis and tumor progression of osteosarcoma in vivo 
(Liu et al., 2015). 
Under inflammatory conditions Areg is expressed in several immune cells, and it plays 
important roles in tissue repair and wound healing (Zaiss et al., 2015). For instance, 
AREG plays a pivotal role in the protection from liver injury (Berasain et al., 2005). 
 
Bone 
The bone is a complex organ that, unlike most organs, is not restricted to one location 
or structure, but rather spread over the whole body in several uniquely shaped ele-
ments (Karsenty and Wagner, 2002). Bone tissue has several functions, including me-
chanical support for muscles, protection of vital organs, regulation of blood calcium 
levels, and sustenance of hematopoiesis. To fulfill these functions, bone tissue is con-
stantly remodeled in a cyclical process, where bone resorption by osteoclasts is con-
stantly counterbalanced by bone formation by osteoblasts (Schneider et al., 2009b). 
Bone development begins with mesenchymal cell condensations, which differentiate 
into chondrocytes and then form a cartilaginous template. The innermost chondrocytes 
further differentiate into hypertrophic chondrocytes, which attract blood vessels and 
direct mineralization of the adjacent extracellular matrix before they die through apop-
tosis. Osteoclasts and capillaries invade the remaining mineralized extracellular matrix, 
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which is then replaced by bone in a process called endochondral ossification. Later, 
during longitudinal growth, this process becomes restricted to the growth plates. In 
some cases the mesenchymal condensations skip the cartilaginous step and directly 
differentiate into osteoblasts. This process is called intramembranous ossification and 
occurs in a few body areas, e.g. the flat bones of the skull (Karsenty and Wagner, 
2002, Schneider et al., 2009b). 
Osteoblasts are the major bone forming cells, which produce several extracellular pro-
teins, including alkaline phosphatase, osteocalcin and type I collagen. The collagen-
rich extracellular matrix built by osteoblasts is termed osteoid. Osteoblasts can become 
inactive bone lining cells or, when entombed within extracellular matrix, osteocytes, 
which are important regulators of bone remodeling. Osteocytes produce sclerostin, 
which mainly inhibits the WNT signaling in osteoblasts and therefore promotes their 
differentiation (Long, 2012). 
Osteoclasts are bone specific multinucleated cells derived from the monocyte/macro-
phage haematopoietic lineage. They attach to the bone and secrete acid and lytic en-
zymes, e.g. tartrat-resistant acid phosphatase (TRAP), to resorb the bone matrix. The 
receptor activator of NF-κb ligand (RANKL) is a key factor for osteoclast differentiation 
and activation. It can be expressed by osteoblasts to stimulate bone resorption via 
binding to its receptor RANK (receptor activator of NF-κb) on the surface of osteoclasts, 
which means that osteoblasts can directly regulate osteoclasts. Another protein regu-
lating osteoclast activity is osteoprotegerin (OPG), which acts as a decoy receptor for 
RANKL and therefore blocks osteoclast formation (Boyle et al., 2003). 
Long bones can be divided in three regions: The midshaft (diaphysis), the metaphyses 
(below the growth plates) and the epiphyses (above the growth plates). The diaphysis 
consists mainly of dense cortical bone, which surrounds the bone marrow cavity. The 
metaphysis and epiphysis are composed of trabecular (cancellous) bone (Clarke, 
2008). 
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Role of EGFR in skeletal biology and pathology 
The EGFR plays an important role in bone development and homeostasis (Schneider 
et al., 2009b). Mice lacking the EGFR are growth retarded and have facial deformities, 
including elongated snouts, underdeveloped mandibulae and a high incidence of cleft 
palate (Miettinen et al., 1995, Miettinen et al., 1999). EGFR-KO mice have an impaired 
trabecular bone formation, a delayed endochondral ossification and an enlarged zone 
of hypertrophic chondrocytes in the growth plate of long bones on embryonic days 16.5 
and 18.5 and on postnatal day 1 (Sibilia et al., 2003, Wang et al., 2004). Calvarial 
osteoblasts from EGFR-KO mice show decreased proliferation and increased differen-
tiation, indicating that normal EGFR signaling in osteoblasts accelerates proliferation, 
but inhibits differentiation, thus keeping osteoblasts in an undifferentiated, pre-mature 
state (Sibilia et al., 2003). Furthermore, EGFR-KO mice showed a delayed recruitment 
of osteoclasts into the hypertrophic cartilage (Wang et al., 2004). 
Due to the early lethality of EGFR-KO mice, the role of EGFR in bone biology at later 
time points could not be characterized. To circumvent this problem, mouse models with 
an extended survival time were generated, including conditional knockout models us-
ing the Cre/loxP system and treatment of mice with tyrosine kinase inhibitors or EGFR 
antibodies. 
Zhang and co-workers generated preosteoblast/osteoblast-specific EGFR-KO mice 
using the Cre/loxP system (Zhang et al., 2011b). In these mice the loxP (floxed) se-
quences are flanking exon 3 of the Egfr gene, and Cre-mediated recombination results 
in a frameshift and two stop codons in exon 4. EGFRflox/flox Col 3.6-Cre mice developed 
no bone phenotype as compared to controls, probably due to residual EGFR activity. 
To further reduce this activity the mice were crossbred with Waved 5 mice (Wa5), 
which contain a point mutation leading to a kinase dead dominant-negative EGFR (Lee 
et al., 2004). 3-month-old EGFRWa5/flox Col 3.6-Cre mice had a significantly reduced 
total and trabecular bone mineral density (BMD) and their femurs were shorter and 
thinner. Additionally, WT mice treated with the EGFR inhibitors gefitinib or erlotinib 
showed a bone phenotype similar to that of EGFRWa5/flox Col 3.6-Cre mice, indicating 
that signaling via the EGFR leads to an anabolic effect in bone (Zhang et al., 2011b). 
This was also confirmed in the same study using Dsk5 mice, in which constitutively 
activation of the EGFR leads to an increased signaling, and therefore to a higher BMD 
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(Fitch et al., 2003, Zhang et al., 2011b). Furthermore, Zhang and co-workers investi-
gated the bone phenotype of heterozygous Wa5 mice in a 129S1/SvImJ background, 
but there were no differences in 1 and 3 months of age (Zhang et al., 2011b). Shortly 
afterwards it was reported that in a different genetic background (C57BL/6), heterozy-
gous Wa5 mice at the age of 3 months have a significantly reduced total BMD in femurs 
and lumbar vertebral bodies (Schneider et al., 2012). 
Additionally, Zhang and co-workers treated 1-month-old rats with the EGFR inhibitor 
gefitinib and these rats exhibited an accumulation of hypertrophic chondrocytes in the 
growth plate as compared to their vehicle treated controls. Osteoclast recruitment was 
reduced due to a decreased Rankl expression in gefitinib-treated rats. Furthermore, 
gefitinib treatment led to a decreased expression of matrix metalloproteinases (MMP9, 
MMP13, MMP14) (Zhang et al., 2011a).  
To generate a chondrocyte-specific EGFR-KO mouse, Zhang and co-workers used the 
same strategy as before, with one Wa5 and one floxed Egfr allele, but a type 2 collagen 
promoter-driven Cre (Col2-Cre) (Zhang et al., 2011a). EGFRWa5/flox Col2-Cre mice had 
an enlarged zone of hypertrophic chondrocytes and a delayed formation of the sec-
ondary ossification center, due to a suppressed excavation of cartilage canals from the 
perichondrium into the cartilage and a reduced expression of matrix metalloprotein-
ases (MMPs) and Rankl in the hypertrophic chondrocytes, which also leads to a de-
layed differentiation, mineralization and apoptosis of these cells (Zhang et al., 2013). 
Osteoclasts do not express functional Egfr, but its ligands can stimulate osteoclast 
formation indirectly by modulating the expression levels of the osteoclast regulatory 
factors Opg and monocyte chemoattractant protein 1 (MCP1) in osteoblasts. EGF-like 
ligands can stimulate the expression of Mcp1 in osteoblasts, which leads to an in-
creased osteoclast activity, and they can inhibit the expression of Opg (Zhu et al., 
2007). 
Overexpression of EGFR ligands in mice leads to ligand-specific effects on bone for-
mation (Schneider et al., 2009b). Mice overexpressing a shortened human EGF pre-
cursor are growth retarded, show an increased proliferation and abnormal accumula-
tion of osteoblasts in the periosteum and endosteum, and have a reduced cortical 
thickness as compared to controls (Chan and Wong, 2000). Overexpression of Btc in 
mice results in round heads, a reduced longitudinal bone growth, and an increased 
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cortical BMD in the appendicular skeleton, which is mainly due to an increased endo-
cortical bone apposition (Schneider et al., 2009a, Schneider et al., 2005). An osteo-
blast-specific overexpression of Areg under the control of the 2.3kb collagen α1 pro-
moter leads to a transient increase in the trabecular bone mass (Vaidya et al., 2015), 
and, conversely, female mice lacking AREG have less trabecular bone as compared 
to their controls (Qin et al., 2005). 
RT-PCR analysis confirmed the expression of Areg, Btc, Egf, Ereg, Hbegf and Egfr 
and Erbb2 in osteoblasts (Qin et al., 2005).  
In vitro studies with the mouse preosteoblastic cell line MC3T3, mouse bone marrow 
osteoblastic cells, and human bone marrow stromal stem cells, revealed that EGF-like 
ligands stimulate osteoblast proliferation and suppress their differentiation and miner-
alization; furthermore, EGFR signaling inhibits the expression of two important osteo-
blast-specific transcription factors: Runx2 and Sp7 (osterix) (Zhu et al., 2011). Micro-
array analysis of osteoblastic cells treated with EGF revealed an immediate increase 
in the mRNA expression levels of the transcription factors Egr1, 2 and 3 with a peak 
after 30 min in MCT3 cells and after 1 h in rat calvarial osteoprogenitors, and EGR2 
was identified to be a key mediator for EGF-induced cell proliferation and survival 
(Chandra et al., 2013). 
Egfr expression is upregulated in bone and soft tissue tumors (Dobashi et al., 2007), 
in osteosarcoma-derived cell lines and in osteosarcomas (Wen et al., 2007). More im-
portantly, EGFR is upregulated in tumors that have a high tendency to metastasize to 
bone, such as breast, lung and prostate cancer (Citri and Yarden, 2006, Di Lorenzo et 
al., 2002, Mishra et al., 2011, Schneider et al., 2009b). Treatment with tyrosine kinase 
inhibitors decreased the growth of human renal carcinoma cells implanted into tibiae 
of nude mice (Weber et al., 2003), inhibited the osteolytic bone destruction in tibiae 
inoculated with a human non-small lung cancer cell line in Scid mice (Furugaki et al., 
2011), and reduced the number of bone metastases of prostate carcinoma (Angelucci 
et al., 2006). Knockdown of the Egfr expression in nude mice with intratibial inoculation 
of bone metastatic breast cancer cells overexpressing Areg reduced the tumor growth 
within the bone (Nickerson et al., 2012). These data underline the prominent role of 
EGFR signaling in bone metastases development. 
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The major mechanism of osteolytic bone destruction in patients with bone metastases 
is tumor-mediated stimulation of bone resorption (Roodman, 2001). EGFR activation 
in cancer cells leads to the production of signaling molecules such as PTHrP (PTH 
related peptide). PTHrP binds the PTH receptor, which leads to an increased Rankl 
expression and therefore stimulates osteoclast activation and differentiation. Interest-
ingly, while AREG was identified as the major EGFR ligand controlling Pthrp expres-
sion in breast cancer cells, blocking autocrine EGFR signaling loops with an AREG 
antibody only resulted in a modestly inhibited motility of breast cancer cells (Gilmore 
et al., 2008, Nickerson et al., 2012). 
Recently, it was shown by Liu and co-workers that Areg is upregulated in two human 
osteosarcoma cell lines (MG63 and U2OS). Furthermore, supplementation of AREG 
increases the migration of these osteosarcoma cells and AREG enhances tumor pro-
gression and cell metastasis of osteosarcoma in vivo, whereas Areg knockdown re-
duced the number of pulmonary metastases (Liu et al., 2015). 
 
Parathyroid hormone 
Parathyroid hormone (PTH) is the major hormonal regulator of bone remodeling and 
calcium homeostasis. PTH is secreted as an 84 aa polypeptide by the parathyroid 
glands in response to low extracellular calcium levels, and binds after being processed 
at its target cells to the PTH receptor, a G-protein-coupled receptor, thus activating 
distinct signaling pathways, e.g. the protein kinase A (PKA) and protein kinase C (PKC) 
pathways (Partridge et al., 2006, Poole and Reeve, 2005). PTH acts on the bone to 
stimulate bone resorption and to increase the release of calcium (Poole and Reeve, 
2005, Swarthout et al., 2002). It indirectly stimulates osteoclasts by increasing the ex-
pression of Rankl in stromal cells and osteoblasts (Teitelbaum, 2000). In the kidney, 
PTH increases tubular calcium re-absorption and synthesis of 1,25-dihydroxyvitamin 
D3, which then enhances the calcium uptake in the intestine. Paradoxically, in addition 
to this classical bone catabolic action, PTH can also act as a bone anabolic agent, 
depending on the pattern of administration. While continuous infusion causes bone 
loss, daily injections of PTH increase bone formation (Poole and Reeve, 2005, Tam et 
al., 1982). Teriparatide, a recombinant 1-34 aa peptide of human PTH, is currently 
used as a treatment for patients with osteoporosis (Sugiyama et al., 2015). 
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The detailed mechanisms behind the anabolic actions of PTH have not yet been fully 
understood. Intermittent injections of PTH increase the number of osteoblasts by stim-
ulating their proliferation and differentiation (Nishida et al., 1994, Pettway et al., 2008), 
attenuating their apoptosis (Bellido et al., 2003, Jilka et al., 1999) and activating bone 
lining cells (Dobnig and Turner, 1995). Over the years several signaling pathways have 
been identified to play an important role in mediating this effect (Schneider et al., 2012), 
including insulin-like growth factor-1 (IGF1) (Miyakoshi et al., 2001), c-fos (Demiralp et 
al., 2002), interleukin-18 (Raggatt et al., 2008), ß-arrestin 2 (Bouxsein et al., 2005) and 
sclerostin (Kramer et al., 2010a). 
Microarrays were used to access PTH-regulated genes in bone (Qin et al., 2003, von 
Stechow et al., 2004) and to compare gene expression profiles between intermittent 
and continuous PTH (1-34) treatment (Onyia et al., 2005). In both treatments Oniya 
and co-workers found increased levels of genes associated with bone formation. Con-
tinuous PTH treatment of rats led to higher expression of genes associated with bone 
turnover and osteoclast formation, such as MMPs and cathepsin K. Intermittent PTH 
treatment led to fewer changes in gene expression levels, and most of the regulated 
genes are associated with receptor binding (e.g. IGF-binding protein 6), immune re-
sponse or catalysis (e.g. carboxypeptidase E). The latter gene was also upregulated 
after continuous PTH treatment, although to a lesser extent. Surprisingly, some genes 
uniquely regulated by intermittent PTH treatment are associated with neuronal tissue 
(Onyia et al., 2005). Shortly afterwards, Li and co-workers presented similar results (Li 
et al., 2007a). Li and co-workers compared gene expression profiles of rats treated 
continuously or intermittently with three different PTH peptides. Intermittent injections 
of PTH (1-31) or PTH (1-34) led to an increased bone formation, whereas PTH (3-34) 
did not. PTH (3-34) activates the PKC pathway, whereas PTH (1-31) activates the PKA 
pathway. These data indicate that the PKC pathway plays a minor role in mediating 
the bone anabolic actions of PTH (Li et al., 2007a).  
Interestingly, Li and co-workers found in the same study that not only continuous PTH 
treatment led to higher expression levels of Rankl, but also intermittent administration. 
Intermittent PTH treatment led to a striking, but transient, increase in Rankl expression, 
whereas Rankl expression was moderately upregulated, but in a persistent manner, 
after continuous treatment. The authors suggest that the bone anabolic effect may be 
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accomplished by a short termed, increased bone resorption and a subsequent in-
creased bone formation (Li et al., 2007a). 
Intermittent administration of PTH rapidly increases the expression of Mcp1 in osteo-
blasts and therefore enhances osteoclast activity (Li et al., 2007b). Recently, it was 
shown that the bone anabolic response after treatment with intermittent PTH is blocked 
in MCP1-KO mice (Tamasi et al., 2013). These data indicate that the osteoclast regu-
lating factor MCP1 is an important mediator for the bone anabolic effect of PTH.  
 
Role of EGFR signaling in mediating the bone anabolic actions of PTH 
There is accumulating evidence that the bone anabolic actions of intermittent PTH 
treatment are, at least in part, mediated via EGFR signaling. Two ligands of the EGFR, 
Areg and Tgfa, were identified as a PTH-regulated genes in rat UMR 106-01 osteo-
blastic cells. Areg expression was increased more than 2-fold after 4h and 12h of rat 
PTH (1-34) treatment (Qin et al., 2003). Additional studies showed an increase in Areg 
mRNA levels in rat calvarial osteoblasts and mouse MC3T3 cells treated with rat PTH 
(1-34), as well as in the femurs of 4-week-old male rats after subcutaneous injections 
of human PTH (1-38), confirming that Areg is a PTH target gene in vitro and in vivo 
(Qin et al., 2005). In vitro, administration of rat PTH (1-34) increased Areg expression 
levels 5-fold in the proliferative phase (day 6) and 23-fold in the mineralization phase 
(day 14) in rat calvarial osteoblasts, whereas the basal Areg expression levels did not 
change during the three phases of proliferation, differentiation and mineralization. In 
vivo, subcutaneous injections of human PTH (1-38) increased Areg expression 12-fold 
after 1h and 2-fold after 4h. Additional experiments revealed that Areg expression is 
also stimulated in rat primay osteoblastic cells after treatment with prostaglandin E2 
and 1,25-dihydroxyvitamin D3, other osteotropic hormones that play important roles in 
bone remodeling (Qin et al., 2005). 
AREG stimulates proliferation and prevents differentiation and mineralization in rat cal-
varial osteoblasts. Addition of AREG to the medium significantly increased the number 
of cells and completely inhibited their mineralization (Qin et al., 2005). In this study, the 
mRNA levels of bone markers, such as Mmp13, alkaline phosphatase, osteocalcin and 
osteonectin, were decreased in day 20 cultures. Western blot analysis revealed that 
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AREG treatment of osteoblastic cells stimulated the phosphorylation of AKT and ERK 
and increased the expression of c-fos and c-jun (Qin et al., 2005). 
Mice lacking AREG show no abnormalities in growth or body weight (Luetteke et al., 
1999). Microcomputed tomography (µ-CT) analysis of the tibial trabecular bone com-
partment of 4-week-old female AREG-KO mice revealed a significant reduction of tra-
becular number, trabecular thickness, connectivity density and percent bone volume, 
and consequently an increase in trabecular separation, whereas there were no differ-
ences in the femoral cortical bone compartment (Qin et al., 2005), indicating that AREG 
plays a critical role in the development of trabecular bone. In line with these findings, 
recent studies of our group revealed a transient increase of trabecular bone mass in 
mice overexpressing Areg specifically in osteoblasts (Vaidya et al., 2015). 
Recently, AREG was identified as a chemotactic factor for mesenchymal progenitors. 
PTH-mediated release of AREG by osteoblastic cells promotes migration of mesen-
chymal progenitors in vitro via AKT and p38MAPK pathways. Conditioned media col-
lected from cells with a siRNA knockdown of Areg do not possess this chemotactic 
activity (Zhu et al., 2012).  
In the latter study, Zhu and co-workers showed that the bone anabolic effect of inter-
mittent PTH injections was blunted in EGFRWa5/flox Col 3.6-Cre mice, which have a re-
duced EGFR activity in osteoblasts, indicating that the bone anabolic actions of PTH 
require EGFR signaling (Zhu et al., 2012). In heterozygous Wa5 mice the bone ana-
bolic effect of intermittent PTH treatment was fully maintained, most likely due to re-
sidual EGFR activity in these mice (Schneider et al., 2012, Zhu et al., 2012). 
 
Aim of the study 
In summary, AREG seems to be the major EGFR ligand mediating the bone anabolic 
actions of PTH. To clarify to which extent AREG is required for the bone anabolic effect 
of PTH, we treated 3-month-old female AREG-KO mice and controls intermittently with 
PTH or vehicle (saline) and examined their bone phenotype in detail. 
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3 Animals, Methods and Materials 
 
Animals 
AREG knockout (AREG-KO) mice were generated by Luetteke et al. (1999) and ob-
tained from The Mutant Mouse Regional Resource Center (MMRRC) Repository at the 
University of North Carolina, USA. The AREG-KO mice were maintained in an inbred 
129/C57BL/6 mixed background and housed under specified pathogen free conditions 
in a closed barrier facility with a 12 h light cycle at 25°C and 45% humidity. Health 
monitoring was performed according to FELASA (Federation of European Laboratory 
Animal Science Associations) recommendations. The mice were housed in Makrolon 
type II long and type III cages enriched with red houses and cellulose paper and had 
free access to standard rodent diet (V1534; Ssniff, Soest, Germany) and filtered tap 
water. The mice were weaned and marked with ear punches at the age of 4 weeks. 
Only females at an age of 3 months were used for the experiment. 
All experiments were carried out in accordance with the German Animal Protection 
Law and authorized by the responsible veterinary authority. 
 
Genotyping 
For genotyping, ear punch tissues were collected in 1.5 ml vials (Eppendorf, Hamburg) 
and stored at -20 °C if not processed immediately. To isolate DNA, 620 µl digestion 
buffer were added to each tube and the samples were incubated overnight at 56 °C 
with gentle shaking. 
Digestion buffer: 0.5 M EDTA pH 8.0      120 µl 
proteinase K (20 mg/ml in bidistilled H2O)  17.5 µl 
Nuclei Lysis Solution    500 µl 
 
After digestion, 3 µl RNAse (4mg/ml in bidistilled water) were added to each vial. The 
samples were incubated for 20 minutes at 37 °C to degrade RNA. Afterwards, to induce 
protein denaturation and precipitation, 200 µl protein precipitation solution were added 
and the samples were vortexed for 20 seconds at high speed and then chilled on ice 
for 5 minutes. The protein pellet was obtained via centrifugation (14 000 x g for 4 
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minutes) and the DNA containing supernatant was carefully transferred to a fresh vial 
containing 600 µl isopropanol to induce DNA precipitation. After gently inverting the 
tube for several times, the samples were centrifuged at 14 000 x g for 2 minutes. The 
supernatant was discarded. The remaining DNA pellet was washed in 600 µl 70% eth-
anol, and a pure pellet was obtained after centrifugation (14 000 x g for 2 minutes) and 
discarding the supernatant. The DNA pellet was air-dried for 10 to 15 minutes and 
rehydrated with 50 µl DNA Rehydration Solution. The DNA samples were stored at 4 
°C. 
Polymerase chain reaction (PCR) was performed using the Taq DNA polymerase Kit 
(Qiagen, Hilden). A mastermix was prepared on ice as follows (calculated per sample): 
 
10x PCR reaction buffer (Qiagen, Hilden)    2.00 μl  
dNTPs, 1 mM (MBI Fermentas, St. Leon-Rot)     2.00 μl  
Q-Solution (Qiagen, Hilden)       4.00 μl  
MgCl2, 25mM (Qiagen, Hilden)       1.25 μl  
Primer AregDel#1, 10 μM        1.00 μl  
Primer AregDel#2, 10 μM        1.00 μl  
Primer AregDel#3, 10 μM        1.00 μl  
Bidistilled H2O         6.65 μl  
Taq Polymerase, 5 U/μl (Qiagen, Hilden)     0.10 μl  
            
          ∑ 19 µl 
 
19 µl mastermix were added to each DNA template (1 µl) in a PCR-reaction tube. 
 
Primer sequences: 
AregDel#1: 5’ CTT TCC AGC TTT CTC CAC CTC AAG 3’ 
AregDel#2:  5’ ACA GTA ACC TCT GTT GCA TGC CAC 3’ 
AregDel#3:  5’ CTG CAC GAG ACT AGT GAG ACG TGC 3’ 
 
Thermal cycler conditions : 
94°C - 5 minutes 
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94°C - 45 seconds 
59°C - 45 seconds 
72°C - 1 minute 
72°C - 10 minutes 
4 °C - paused (till further process) 
 
The amplified products and molecular weight marker were loaded on a 1.5% agarose 
TAE gel containing ethidium bromide. Electrophoresis was carried out for 40 min at 
120 Volt with TAE running buffer. The amplified DNA bands were visualized with ultra-
violet light. 
The primers AregDel#1 (sense) and AregDel#2 (antisense) both bind in the intron re-
gion before exon 3, leading to a ≈ 330 bp wild type allele signal. In AREG-KO mice, 
exons 3 and 4 are replaced by a neomycin cassette (Luetteke et al., 1999). The primer 
AregDel#3 (antisense) binds to this cassette, leading to a ≈ 600 bp signal for the knock-
out allele. 
The 50x TAE stock contained: 
TRIS    242 g  
Glacial acetic acid  57.1 ml  
0.5M EDTA pH 8.0  100 ml 
ad 1000 ml bidistilled H2O 
 
PTH treatment 
3-month-old female AREG KO mice and WT controls received either 80µg/kg body 
weight (1-34) PTH (Bachem, Weil am Rhein, Germany) or vehicle (0.9% physiological 
saline solution) by subcutaneous injection once daily for five days per week over a 
period of four weeks. Additionally, all mice were subcutaneously injected with alizarin 
complexone (30 mg/kg body weight) once at the beginning of the experiment and with 
calcein (20 mg/kg body weight) on days 4 and 2 prior to necropsy. 
36 x 
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Figure 3 Schematic overview of the subcutaneous PTH and fluorochrome injections over the whole time 
of the experiment. AREG-KO and WT mice were subcutaneously injected with PTH (1-34) (80 mg/kg) 
or physiological saline five times a week for four weeks. Additionally, all animals received an injection 
with alizarine complexone (30 mg/kg) at the beginning of the experiment and calcein on days 4 and 2 
before sacrifice. 
 
Urine, serum and tissue collection 
Spontaneous urine was collected and frozen at -20 °C until further analysis. Anesthe-
tized mice were bled form the retrobulbar venous plexus with a heparinized capillary. 
To obtain serum, the blood samples were centrifuged for two times at 664 x g for 10 
minutes in 1.5 ml centrifuge tubes and stored at -80°C until further analysis. The femurs 
and the first lumbar vertebrae (L1) were removed and cleaned. 
 
Tissue preparation for histology and histomorphometry 
Preparation of femurs and L1 for histology and histomorphometry was performed as 
described previously (Erben, 1997, Reim et al., 2008, Schneider et al., 2009a). First, 
the bones were fixed in 4% paraformaldehyde in PBS at 4 °C for 24h under gentle 
Alizarin complexone (30mg/kg) s.c. injection
Calcein (20mg/kg) s.c. injection
PTH (1-34) (80µg/kg) s.c. injection
Control group: physiological saline
 sacrifice
D7 D9 D11 D13
D14 D16 D18 D20
D21 D23 D25 D27
D0 D2 D4 D6
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shaking. Afterwards, the bones were washed with PBS for 24h at 4°C under gentle 
shaking. 
The 10x PBS stock contained: 
NaCl      80.0 g 
Na2HPO4     14.4 g 
KCl      2.0 g 
KH2PO4     2.4 g 
ad 1000 ml bidistilled H2O 
pH was adjusted to 7.4 
 
After fixation and washing, the femurs and L1 were stored in 70% ethanol until further 
process. The right femur was cut in half using a precision band saw (Exakt, Norder-
stedt, Germany). The distal part of the femur and L1 were subsequently dehydrated 
and embedded in methylmethacrylate (MMA). 
Dehydration: 
Day 1: 96% ethanol 
Day 2: isopropanol 
Day 8  xylene 
Day 14: MMA I 
Day 18: MMA II 
Day 21: MMA III 
Day 25: embedding 
 
MMA I contained: 
MMA      600 ml 
Butylmethacrylate    50 ml 
Methylbenzoate    50 ml 
Polyethylglycol 400    12 ml 
ad 1000 ml bidistilled H2O 
 
MMA II contained: 
MMA      600 ml 
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Butylmethacrylate    50 ml 
Methylbenzoate    50 ml 
Polyethylglycol 400    12 ml 
Benzylperoxide    4g 
Ad 1000 ml bidistilled H2O 
 
MMA III contained: 
MMA      600 ml 
Butylmethacrylate    50 ml 
Methylbenzoate    50 ml 
Polyethylglycol 400    12 ml 
Benzylperoxide    8g 
ad 1000 ml bidistilled H2O 
 
For embedding, 4 ml/l N,N-Dimethyl-toluidine was added to MMA III to induce polymer-
ization. The bones were embedded in 10 ml glass vials with a previously prepared 
plastic layer on the bottom. The vials were sealed with parafilm and transferred to a 
cooling chamber (-18 °C to -23 °C for 5 days). 
After removing the glass vial and trimming the plastic block, 3-µm-tick sections of the 
femoral metaphysis and of the vertebral bodies were cut using a Microm HM360 mi-
crotome with a tungsten carbide knife. During cutting, the sections were kept wet with 
0.1 % TWEEN® 20 and transferred carefully to APES-coated microscope slides. 
For APES coating, the microscope slides were first incubated with aceton for 10 
minutes and afterwards shortly rinsed with tap water. Thereafter, the slides were again 
incubated with aceton for 5 minutes and then incubated with APES solution, containing 
4 ml APES in 200 ml Aceton. After APES coating, the slides were washed twice in 
bidistilled H2O and incubated at 40°C-50°C overnight. 
After transferring the sections to the APES-coated microscope slides, the sections 
were carefully stretched using 70 % ethanol, covered with polyethylene foil and 
pressed with a slide press for 3-4 days at 42 °C. 
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To obtain cross-sections of the femoral mid-diaphysis, the left femur was also embed-
ded in MMA and 200-µm-sections were taken using a precision band saw. Subse-
quently, the sections were grounded to a final thickness of 20 µm using a micro-grind-
ing system (Exakt Norderstedt, Germany). The sections were carefully glued on APES-
covered microscopy slides. 
 
Kossa/McNeal staining 
To analyze bone formation, the longitudinal sections of the right femur and sections of 
the first lumbar vertebral bodies were stained with Kossa/McNeal tetrachrome accord-
ing to standard protocols (Erben, 1997). The sections were deplastinized with methox-
yethylacetat (for 60 minutes) and aceton (for 10 minutes) and washed with bidistilled 
H2O (for 10 minutes). Next, the sections were incubated with 5% silver nitrate solution 
for 5-10 minutes (protected from light). After rinsing with bidistilled H2O, the sections 
were incubated in a solution containing 5 % sodium carbonate and 9.25 % formalde-
hyde in bidistilled H2O for 2 minutes. The sections were again rinsed with bidistilled 
H2O and then incubated for 30 seconds in Farmer’s Reducer. After rinsing under run-
ning tap water for 20 minutes and quickly washing with bidistilled H2O, the sections 
were stained in a 5 % tetrachrome solution for 60 minutes. Thereafter, the slides were 
again rinsed in bidistilled H2O and dehydrated with isopropanol and xylene. The slides 
were mounted with DePex (SERVA Electrophoresis GmbH, Heidelberg). 
The Farmer’s Reducer solution contained: 
Sodium thiosulfate 10 %   200 ml 
Potassium ferrocyanide 10 %  10 ml 
 
The 5 % tetrachrome solution contained: 
Methylene blue    0.5 g 
Azur-A-Eosinat     0.8 g 
Methylene violet    0.1 g 
Methanol     250 ml 
Glycerol     250 ml 
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Analysis of the osteoblast surface and the osteoid was performed using OsteoMeasure 
3.0 (OsteoMetrics, Decatur, GA, USA) software, the DrawingBoard VI (GTCO Cal-
Comp, Scottsdale, AZ, USA) and the Axioskop 2 Plus (C. Zeiss, Jena, Germany). The 
area within 0.25 mm from the growth plates was excluded from the measurements. 
 
Tartrate resistant alkaline phosphatase (TRAP) staining 
To analyze bone resorption, the longitudinal sections of the right femur were stained 
for tartrate resistant alkaline phosphatase (TRAP) enzyme activity according to stand-
ard protocols (Erben, 1997, Schmidt et al., 1999). The sections were deplastinized with 
methoxyethylacetat (for 60 minutes) and with aceton (for 10 minutes) and washed with 
bidistilled H2O (for 10 minutes). Next, the sections were incubated in 0.2 M acetate 
buffer pH 5.0 for 20 minutes and afterwards with TRAP-reagent for 2-4 hours at 37°C. 
The slides were shortly rinsed with bidistilled H2O, counterstained with Mayer’s hema-
toxylin for 3 minutes and rinsed with tap water for 5-10 minutes. The stained sections 
were mounted with Kaiser’s glycerol galantine (Merck, Darmstadt), an aqueous mount-
ing medium. 
The TRAP reagent contained: 
naphtol AS-MX phosphate disodium salt  0.5 mg/ml  
fast red TR salt     1,1 mg/ml 
disolved in 0.2 M acetate buffer pH 5.0 
 
The hematoxylin staining solution contained: 
Hematoxylin     1 g 
Sodium iodide     0.2 g 
Aluminium potassium sulfate  50 g 
Chloral hydrate    50 g 
Citric acid     1 g 
Ad 1000 ml bidistilled H2O 
 
Analysis of osteoclast numbers was performed using OsteoMeasure 3.0 (OsteoMet-
rics, Decatur, GA, USA) software, the DrawingBoard VI (GTCO CalComp, Scottsdale, 
AZ, USA) and the Axioskop 2 Plus (C. Zeiss, Jena, Germany). The area within 0.25 
mm from the growth plates was excluded from the measurements. 
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Toluidine blue staining 
Toluidine blue staining and automatic image analysis of cross-sections of the femoral 
mid-diaphysis were performed as described previously (Erben, 1997, Reim et al., 
2008, Weber et al., 2004). First, the 20-µm undeplasticized microground sections were 
incubated with 30 % H2O2 under gentle shaking. After shortly rinsing the sections in 
tap water, the sections were stained in toluidine blue staining solution for 60 minutes. 
 
The toluidine staining solution contained: 
Toluidine blue O    2 g 
Di-Sodium hydrogen phosphate   75 mg 
Citric acid      158 mg 
ad 100 ml bidistilled H2O 
 
After staining and air-drying for 2 hours, the sections were mounted with DePex. 
Automatic image analysis was performed using the AxioVision 4.6 (C. Zeiss, Jena, 
Germany) software. 
 
Mounting with Fluoromount 
To measure the cortical mineral apposition rate (MAR) and the trabecular bone for-
mation rate (BFR), undeplasticized and unstained longitudinal sections of the distal 
femoral metaphysis, cross-sections of the femoral mid-diaphysis and sections of the 
first lumbar vertebral bodies were mounted with Fluoromount (Serva, Heidelberg, Ger-
many) as described previously (Erben, 1997). 
Analysis of the trabecular BFR and the cortical MAR was performed using Osteo-
Measure 3.0 (OsteoMetrics, Decatur, GA, USA) software, the DrawingBoard VI (GTCO 
CalComp, Scottsdale, AZ, USA) and the Axioskop 2 Plus (C. Zeiss, Jena, Germany). 
The border of the trabecular and cortical bone were traced under blue violet excitation 
(395-440 nm) and the calcein and alizarin complexone labels were traced under blue 
excitation (450-490 nm) to reduce background. In the distal femoral metaphysis and in 
L1, the area within 0.25 mm from the growth plates was excluded from the measure-
ments. 
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Biochemical bone markers 
Analysis of biochemical bone markers was kindly conducted by Claudia Bergow from 
the laboratory of Prof. Reinhold Erben, Vienna, Austria. Serum osteocalcin levels were 
measured with an immunoradiometric assay (Mouse Osteocalcin ELISA kit, Immu-
topics International) according to the manufacturer's instructions. Total collagen cross-
link deoxypyridinoline was measured with the MicroVue DPD EIA kit (Quidel Corpora-
tion, USA) according to the manufacturer's instructions and normalized to urinary cre-
atinine levels, measured with a Cobas c111 autoanalyzer (Roche Diagnostics). 
 
Statistical analyses 
Statistical analyses were performed using the SPSS software for Windows 17.0 (SPSS 
Inc., Chicago, USA). Differences between the groups were analyzed by one-way 
ANOVA followed by Student-Newman-Keuls (SNK) test as post hoc test. Additionally, 
the data were analyzed by two-way ANOVA to evaluate the individual effects of PTH 
treatment and the knocked out Areg gene, as well as their 2-way interaction. The 
graphs were generated with GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, 
USA). P values lower than 0.05 were considered significant. The data are presented 
as means ± SEM. 
 
Materials 
 
Machines and software 
Agarose gel electrophoresis chamber  MWG-Biotech, Ebersberg, Germany 
Axioskop 2 Plus      C. Zeiss, Jena, Germany 
AxioVision 4.6      C. Zeiss, Jena, Germany 
Band Saw  EXAKT Apparatebau GmbH, Nor-
derstedt, Germany 
Centrifuge (5417R)  Eppendorf, Hamburg, Germany 
Cobas c111 autoanalyzer    Roche Diagnostics, Germany 
GraphPad Prism 5.0 GraphPad Software Inc., La Jolla, 
USA 
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Incubator  Thermo Fisher Scientific, Schwerte, 
Germany 
Microgrinding System  EXAKT Apparatebau GmbH, Nor-
derstedt, Germany 
Micrometer  Mitutoyo Deutschland GmbH, In-
golstadt, Germany 
Microtome HM 360  Microm International GmbH, Waldorf, 
Germany 
Microwave      Siemens, München, Germany 
MS1 Minishaker  IKA process equipment, Staufen 
OsteoMeasure 3.0   OsteoMetrics, Decatur, GA, USA 
SPSS SPSS Inc., Chicago, USA 
Thermocycler   Biometra®, Göttingen, Germany 
Thermomixer  Eppendorf, Hamburg, Germany 
Wise Shake® Shaker, SHR-1D Wisd Laboratory Instruments, Labora-
tory Supplies Ltd., Dublin, Ireland 
 
Consumables 
Filter paper circles, Ø 150 mm  Whatman GmbH, Dassel, Germany 
Glass microscope slides  Menzel-Gläser, Braunschweig, Ger-
many 
Grinding disks  Hermes Schleifmittel, Hamburg, Ger-
many 
Microscope cover glasses, 24 x 50 mm  VWR International, Darmstadt, Ger-
many 
Microscope cover glasses, 18 x 18 mm  VWR International, Darmstadt, Ger-
many 
Parafilm  VWR International, Darmstadt, Ger-
many 
Pasteur pipette, 5 ml  VWR International, Darmstadt, Ger-
many 
Pasteur pipette, 7 ml VWR International, Darmstadt, Ger-
many 
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Polyethylene foil  Heraeus Kulzer GmbH, Hanau, Ger-
many 
QualiPCRTube-strips   Kisher Biotech, Steinfurt, Germany 
Safe-lock tubes, 1.5 ml  Eppendorf, Hamburg, Germany 
Standard rodent diet (V1534)   Ssniff, Soest, Germany 
Tungsten carbide knife  Microm International GmbH, Waldorf, 
Germany 
 
Chemicals 
Agarose  Invitrogen, Karlsruhe, Germany 
Alizarine complexone Sigma-Aldrich, Schnelldorf, Germany 
APES (Aminopropyltriethoxysilane)  Sigma-Aldrich, Deisenhofen, Germany 
Azur-A-Eosin     Merck, Darmstadt, Germany 
Benzylperoxide     Merck, Darmstadt, Germany 
Butylmethacrylate  Sigma-Aldrich, Deisenhofen, Germany 
Calcein  Sigma-Aldrich, Schnelldorf, Germany 
DePex  SERVA Electrophoresis GmbH, Hei-
delberg, Germany 
DNA Rehydration Solution  Promega, Mannheim, Germany 
dNTPs  Thermo Scientific, St. Leon-Roth, Ger-
many 
EDTA       VWR, Darmstadt, Germany 
Ethanol   Carl Roth, Karlsruhe, Germany 
Ethidiumbromide   Carl Roth GmbH, Karlsruhe, Germany 
Fast Red TR  Sigma-Aldrich, Deisenhofen, Germany 
Fluoromount  SERVA Electrophoresis GmbH, Hei-
delberg, Germany 
Formaldehyde Solution, 37 %   Merck, Darmstadt, Germany 
Gene Ruler, 100 bp  Thermo Scientific, St. Leon-Roth, Ger-
many 
Glacial acetic acid  Carl Roth, Karlsruhe, Germany 
Glycerol  Merck Schuchardt, Hohenbrunn, Ger-
many 
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Hematoxylin  Merck, Darmstadt, Germany 
Hydrogen peroxide, 30 %  Merck Schuchardt, Hohenbrunn, Ger-
many 
Isopropanol       VWR, Darmstadt, Germany 
Kaiser’s glycerol gelantine    Merck, Darmstadt, Germany 
KCl       Merck, Darmstadt, Germany 
KH2PO4       Merck, Darmstadt, Germany 
Loctite ® 420 glue Henkel AG & Co. KGaA, Düsseldorf, 
Germany 
Methoxyethyl acetate    Merck, Darmstadt, Germany 
Methyl alcohol  Sigma-Aldrich, Deisenhofen, Germany 
Methylbenzoate     Merck, Darmstadt, Germany 
Methylene blue     Merck, Darmstadt, Germany 
Methylene violet  Chroma-Gesellschaft Schmid & Co., 
Stuttgart-Untertürkheim, Germany 
Methylmethacrylate     Merck, Darmstadt, Germany 
MicroVue DPD EIA kit     Quidel Corporation, USA 
Mouse Osteocalcin ELISA kit   Immutopics International, USA 
Na2HPO4      Merck, Darmstadt, Germany 
Naphtol AS-MX phosphate  Sigma-Aldrich, Deisenhofen, Germany 
N,N-Dimethyl-toluidine  Merck, Darmstadt, Germany  
Nuclei Lysis Solution   Promega, Mannheim, Germany 
Paraformaldehyde  Sigma-Aldrich, Deisenhofen, Germany 
Polyethylglycol     Merck, Darmstadt, Germany 
Potassium ferrocyanide  Sigma-Aldrich, Deisenhofen, Germany 
Protein Precipitation Solution   Promega, Mannheim, Germany 
Proteinase K, 20 mg/ml    Roche, Mannheim, Germany 
PTH  Bachem, Weil am Rhein, Germany 
RNAse   Promega, Mannheim, Germany 
Silver nitrate      Merck, Darmstadt, Germany 
Sodium acetate     Merck, Darmstadt, Germany 
Sodium carbonate     Merck, Darmstadt, Germany 
Sodium iodide  Sigma-Aldrich, Deisenhofen, Germany 
Sodium thiosulfate pentahydrate , 10%  Merck, Darmstadt, Germany 
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Taq DNA Polymerase Kit    Qiagen, Hilden, Germany 
Tartratic acid      Merck, Darmstadt, Germany 
TRIS  Carl Roth, Karlsruhe, Germany 
TWEEN ® 20  Sigma-Aldrich, Deisenhofen, Germany 
Xylene  Herba Chemosan Apotheker AG, 
Wien, Austria 
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4 Results 
 
Cortical bone histomorphometry of the femoral shaft 
Analysis of cross-sections of the femoral mid-diaphysis revealed a profound increase 
of periosteal and endocortical bone in the PTH-treated AREG-KO and WT mice as 
compared to their saline-treated controls, as shown by the red alizarine complexone 
line given at the start of the experiment. Measurement of the periosteal and endocor-
tical mineral apposition rate (MAR) confirmed these findings. Both the periosteal and 
the endocortical MAR were significantly increased in PTH-treated AREG-KO and WT 
mice as compared to their controls. 
 
Figure 4 Fluorochrome labeling showing the newly formed cortical bone over the whole 4-week exper-
imental period as shown by the red alizarin complexone line. Graphs show the periosteal and the endo-
cortical mineral apposition rate (MAR). Data are means ± SEM of 13-14 animals/group. * denotes p < 
0.05 vs. the respective vehicle-treated group. Results of 2-way ANOVA are shown below the graphs. 
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Figure 5 Toluidine blue-stained histological pictures of 20-µm microground cross-sections of the femo-
ral midshaft showing an increase of cortical bone in the PTH-treated AREG-KO and WT mice as com-
pared to their saline-treated controls. 
 
Toluidine blue-stained histological sections of the femoral midshaft also showed an 
increase of cortical bone in the PTH-treated AREG-KO and WT mice as compared to 
their control groups. However, automatic image analysis of toluidine blue-stained 20-
µm-thick microground sections of the femoral midshaft showed only mild changes. The 
cortical area (Ct.Ar) and the cortical thickness (Ct.Th) were increased in PTH-treated 
WT mice as compared to their saline-treated controls, whereas the total (cross-sec-
tional) area (TtCross-sectAr), the marrow area (Ma.Ar) and its relation to the total area, 
the intracortical pore area (hole area, HoleAr) and its relation to the total area, the 
intracortical pore number (hole number, HoleNo), the pore perimeter (hole perimeter, 
HolePm), the cortical area (Ct.Ar) in its relation to the total area (Ct.Ar/Tt.Ar.), the bone 
perimeter (B.Pm), the periosteal (Ps.BPm) and endocortical bone perimeter (Ec.BPm) 
were unchanged between the groups as shown in Figures 6a and 6b. No differences 
were seen between saline-treated WT and AREG-KO mice. 
In conclusion, the bone anabolic effect of intermittent PTH treatment was fully main-
tained in the femoral cortical bone of AREG-KO mice. 
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Figure 6a Automatic image analysis of toluidine blue-stained 20-µm microground cross-sections of the 
femoral midshaft. The cortical thickness (Ct.Th) and area (Ct.Ar) were increased in WT mice after four 
weeks of PTH treatment as compared to their saline-treated controls. The cortical area in relation to the 
total area (Ct.Ar/Tt.Ar) remained unchanged. No differences were found in total cross-sectional area 
(TtCross-sectAr), marrow area (Ma.Ar) and its relation to the total area. Data are means ± SEM of 9-10 
animals/group. * denotes p < 0.05 vs. the respective vehicle-treated group. Results of 2-way ANOVA 
are shown below the graphs.  
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Figure 6b Automatic image analysis of toluidine blue-stained 20-µm microground cross-sections of the 
femoral midshaft. No differences between the groups were found in bone perimeter (B.Pm), the perios-
teal (Ps.BPm) and endocortical bone perimeter (Ec.BPm), the intracortical pore area (hole area, HoleAr) 
and in its relation to the total area, in the number of intracortical pores (hole number, HoleNo) or their 
perimeter (HolePm). Data are means ± SEM of 9-10 animals/group. * denotes p < 0.05 vs. the respective 
vehicle-treated group. Results of 2-way ANOVA are shown below the graphs. 
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Cancellous bone histomorphometry of the distal femoral metaphysis 
Histology of Kossa/McNeil-stained longitudinal sections of the distal femoral metaphy-
sis revealed a profound increase of cortical and cancellous bone in both PTH-treated 
groups as compared to their saline-treated controls. 
 
Figure 7 Kossa/McNeil-stained longitudinal sections of the distal femur showing an increase of bone 
mass in the PTH-treated WT and AREG-KO mice as compared to their saline-treated controls.  
 
Analysis of Kossa/McNeil-stained sections of the distal femoral metaphysis showed 
that the osteoblast surface (in relation to the bone surface, Ob.S/BS), the osteoid sur-
face (in relation to the bone surface, OS/BS) and the osteoid volume (in relation to the 
bone volume, OV/BV) were unchanged between the groups. The osteoid thickness 
(O.Th) was increased in PTH-treated WT mice as compared to their saline-treated 
controls and the same tendency was seen in PTH-treated AREG-KO animals as com-
pared to their controls as shown in Figure 8. 
The mineral apposition rate (MAR) and the bone formation rate (BFR) were increased 
in both PTH-treated groups as compared to their vehicle-treated controls as shown in 
Figure 9. The amount of newly formed trabecular bone was measured by the distance 
between the two green calcein labels. No significant differences were found between 
saline-treated AREG-KO and WT mice and PTH-treated AREG-KO and WT mice. 
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Figure 8 Analysis of Kossa/McNeil-stained longitudinal sections of the distal femur showing no differ-
ences in Ob.S./BS (osteoblast surface in relation to bone surface), in OS/BS (osteoid surface in relation 
to bone surface) and OV/BV (osteoid volume in relation to bone volume). The osteoid thickness (O.Th) 
was increased in PTH-treated WT mice as compared to their saline-treated controls. Data are means ± 
SEM of 13-14 animals/group. * denotes p < 0.05 vs. the respective vehicle-treated group. Results of 2-
way ANOVA are shown below the graphs. 
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Figure 9 Mineral apposition rate (MAR) and bone formation rate (BFR) were increased in the distal 
femoral metaphysis in PTH-treated WT and AREG-KO mice as compared to their saline-treated con-
trols. Data are means ± SEM of 13-14 animals/group. * denotes p < 0.05 vs. the respective vehicle-
treated group. Results of 2-way ANOVA are shown below the graphs. 
 
 
Figure 10 Analysis of TRAP-stained longitudinal cross-sections of the femoral metaphysis to analyze 
bone resorption showing an increased number of osteoclasts per tissue area (N.Oc/T.Ar) and per bone 
perimeter (N.Oc/B.Pm) in PTH-treated WT mice as compared to their saline-treated controls. The num-
ber of osteoclasts per bone perimeter (N.Oc/B.Pm) was significantly lower in PTH-treated AREG-KO 
mice as compared to PTH-treated WT mice. Data are means ± SEM of 14 animals/group. * denotes p 
< 0.05 vs. the respective vehicle-treated group unless stated otherwise. Results of 2-way ANOVA are 
shown below the graphs. 
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Analysis of TRAP-stained sections of the femoral metaphysis revealed an increased 
number of osteoclasts per tissue area (N.Oc/T.Ar) in PTH-treated WT mice as com-
pared to saline-treated WT mice. The same tendency was seen in PTH-treated AREG-
KO mice as compared to their saline-treated controls. Interestingly, the number of os-
teoclasts per bone perimeter (N.Oc/B.Pm) was increased in PTH-treated WT mice as 
compared to their saline-treated controls, whereas no such tendency was seen in the 
PTH- and vehicle-treated AREG-KO mice. On the contrary, the number of osteoclasts 
per bone perimeter was significantly decreased in PTH-treated AREG-KO mice in com-
parison to their WT control as shown in Figure 10. 
Automatic image analysis of Kossa/McNeil-stained sections of the distal femoral met-
aphysis revealed an PTH-mediated increase in the trabecular area (Tb.Ar), the bone 
area in its relation to the tissue area (B.Ar/T.Ar), the bone perimeter in its relation to 
the tissue area (B.Pm/T.Ar), the trabecular number (Tb.N), the trabecular width (Tb.Wi) 
and the bone surface in relation to the tissue volume (BS/TV) in both PTH-treated WT 
and AREG-KO mice as compared to their vehicle-treated controls. Because of the in-
creased number of trabeculae and their increased area and width, the trabecular sep-
aration was decreased in PTH-treated WT and AREG-KO mice in comparison to their 
saline-treated controls. The trabecular number per bone area (N.Tb/B.Ar) was de-
creased in PTH-treated WT and AREG-KO mice as compared to their saline-treated 
controls. The number of trabeculae in relation to the tissue area (N.Tb/T.Ar) was de-
creased in PTH-treated WT mice as compared to their vehicle-treated control. The 
results of the automatic image analysis of the femoral metaphysis are shown in Figures 
11a and 11b. 
In summary, absence of AREG did not alter the effects of intermittent PTH treatment. 
The bone anabolic effect was maintained in the femoral trabecular bone compartment 
of AREG-KO mice. However, the number of osteoclasts per bone perimeter 
(N.Oc/B.Pm) was decreased in PTH-treated AREG-KO mice as compared to their WT 
control, indicating a decreased osteoclast formation under PTH-mediated bone ana-
bolic conditions in AREG-KO mice. 
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Figure 11a Automatic image analysis of Kossa/McNeil-stained longitudinal cross-sections of the distal 
femoral metaphysis showing an increase in the trabecular area (Tb.Ar), the bone area in its relation to 
the tissue area (B.Ar/T.Ar), the bone perimeter in its relation to the tissue area (B.Pm/T.Ar) and the 
trabecular number (Tb.N) in PTH-treated WT and AREG-KO mice as compared to their saline-treated 
controls. The number of trabeculae per bone area (N.Tb/B.Ar) was decreased in PTH-treated WT and 
AREG-KO mice in comparison to their saline-treated controls. Data are means ± SEM of 13-14 ani-
mals/group. * denotes p < 0.05 vs. the respective vehicle-treated group. Results of 2-way ANOVA are 
shown below the graphs.  
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Figure 11b Automatic image analysis of Kossa/McNeil-stained longitudinal cross-sections of the distal 
femoral metaphysis showing a decreased number of trabeculae in relation to the tissue area (N.Tb/T.Ar) 
in PTH-treated WT mice as compared to their saline-treated controls. The trabecular width (Tb.Wi) was 
increased in both PTH-treated WT and AREG-KO mice as compared to their saline-treated controls, 
and vice versa, the trabecular separation (Tb.Sp) was decreased. The relation of the bone surface to 
the tissue volume (BS/TV) was increased in PTH-treated WT and AREG-KO mice in comparison to their 
saline-treated controls. Data are means ± SEM of 13-14 animals/group. * denotes p < 0.05 vs. the 
respective vehicle-treated group. Results of 2-way ANOVA are shown below the graphs. 
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Cancellous bone histomorphometry of the first lumbar vertebra 
The amount of newly formed trabecular bone was measured by the distance of the two 
green calcein labels under fluorescent light in midsagittal sections of first lumbar (L1) 
vertebral bodies. The mineral apposition rate (MAR) was increased in PTH-treated WT 
mice in comparison to their vehicle-treated control, whereas there were only mild 
changes in the PTH-treated AREG-KO mice as compared to their controls. In line with 
the findings in the trabecular bone compartment of the distal femoral metaphysis, the 
bone formation rate (BFR) was increased after intermittent PTH treatment in both WT 
and AREG-KO mice as compared to their saline-treated controls as shown in Figure 
12. 
 
 
Figure 12 Mineral apposition rate (MAR) and bone formation rate (BFR) of the trabecular bone in the 
first lumbar vertebra. The MAR was increased in PTH-treated WT mice as compared to their saline-
treated controls. The BFR was increased in both PTH-treated WT and AREG-KO mice as compared to 
their controls. Data are means ± SEM of 14 animals/group. * denotes p < 0.05 vs. the respective vehicle-
treated group. Results of 2-way ANOVA are shown below the graphs. 
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Figure 13a Automatic image analysis of Kossa/McNeil-stained first lumbar vertebral bodies showing an 
increase of the bone area in its relation to the tissue area (B.Ar/T.Ar), the bone perimeter in its relation 
to the tissue area (B.Pm/T.Ar) and the trabecular number (Tb.N) in PTH-treated WT and AREG-KO mice 
as compared to their saline-treated controls. No significant differences were seen in the trabecular area 
(Tb.Ar) and the number of trabeculae in relation to the bone area (N.Tb/B.Ar). Data are means ± SEM 
of 13-14 animals/group. * denotes p < 0.05 vs. the respective vehicle-treated group. Results of 2-way 
ANOVA are shown below the graphs. 
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Figure 13b Automatic image analysis of Kossa/McNeil-stained first lumbar vertebral bodies showing an 
increase in the bone surface in its relation to the tissue volume (BS/TV) in both PTH-treated WT and 
AREG-KO mice as compared to their saline-treated controls. No significant differences were seen in the 
number of trabeculae in relation to the tissue area (N.Tb/T.Ar) and the trabecular width (Tb.Wi). The 
trabecular separation (Tb.Sp) was decreased in PTH-treated WT and AREG-KO mice as compared to 
their controls. Data are means ± SEM of 13-14 animals/group. * denotes p < 0.05 vs. the respective 
vehicle-treated group. Results of 2-way ANOVA are shown below the graphs. 
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Automatic image analysis of Kossa/McNeil-stained sections of the first lumbar verte-
bral bodies revealed an increase in the bone area in its relation to the tissue area 
(B.Ar/T.Ar), the bone perimeter in its relation to the tissue area (B.Pm/T.Ar), the tra-
becular number (Tb.N) and the bone surface in relation to the tissue volume (BS/TV) 
in both PTH-treated WT and AREG-KO mice as compared to their saline-treated con-
trols as shown in Figures 13a and 13b. These findings were in line with the previous 
results of the trabecular bone compartment in the distal femoral metaphysis. The tra-
becular separation (Tb.Sp) was decreased in both PTH-treated groups as compared 
to their vehicle-treated controls. The trabecular area (Tb.Ar), the number of trabeculae 
in its relation to the bone area (N.Tb/B.Ar), the number of trabeculae in relation to the 
tissue area (N.Tb/T.Ar) and the trabecular width (Tb.Wi) remained unaffected by inter-
mittent PTH treatment in both WT and AREG-KO mice. 
 
Analysis of serum Osteocalcin and urinary deoxypyridinoline 
To evaluate the effect of intermittent PTH treatment at the whole body level, the serum 
level of osteocalcin, a systemic marker for bone formation, and the excretion of urinary 
collagen crosslink deoxypyridinoline (DPD), a marker for bone resorption, were meas-
ured by ELISA. 
Serum osteocalcin was increased in PTH-treated WT and AREG-KO mice as com-
pared to their vehicle-treated controls as shown in Figure 14. These findings were in 
line with the increased BFR in the trabecular and cortical bone compartment, further 
suggesting that intermittent PTH treatment might lead to an increased bone anabolism 
at the whole body level in both WT and AREG-KO mice and that this effect might not 
only be restricted to the femur and the first lumbar vertebra, but also present at the 
whole body level.  
The level of urinary DPD remained unchanged by intermittent PTH treatment in WT 
and AREG-KO mice, indicating that the possible effect of intermittent PTH treatment 
on bone resorption could not be assessed with this marker. The results of urinary DPD 
levels are shown in Figure 14. 
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Figure 14 Serum osteocalcin and urinary deoxypyridinoline/creatinine (DPD/Crea) levels in vehicle and 
PTH-treated WT and AREG-KO mice after 4 weeks of intermittent PTH treatment. Serum osteocalcin 
was increased in both PTH-treated WT and AREG-KO mice as compared to their saline-treated controls, 
whereas urine DPD remained unchanged. Data are means ± SEM of 12-14 animals/group. * denotes p 
< 0.05 vs. the respective vehicle-treated group by 1-way ANOVA followed by SNK test. Results of 2-
way ANOVA are shown below the graphs. 
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5 Discussion 
 
To investigate to which extent AREG is required for the bone anabolic actions of PTH, 
we treated AREG-KO mice and their WT controls intermittently with PTH (1-34) or ve-
hicle (saline) and their bone phenotype was evaluated in detail. In addition to bone 
histomorphometry, µ-CT analysis was kindly conducted by Mithila Vaidya of the labor-
atory of Prof. Reinhold Erben, Vienna, Austria. Furthermore, to investigate the role of 
AREG in bone development and homeostasis in vivo, the bone phenotype of 3- and 8-
month-old AREG-KO and WT mice was analyzed by µ-CT. The results of the study 
were published in Molecular and Cellular Endocrinology (Jay et al., 2015). In summary, 
our data indicate that AREG plays only a minor role in bone homeostasis in non-grow-
ing mice and is not required for the bone anabolic actions of intermittent PTH. 
In AREG-KO mice, the deletion of exons 3 and 4 eliminates all three disulfide bounds, 
the heparin-binding region and the transmembrane domain of Pro-AREG. Additionally, 
splicing of exon 2 to exon 5 leads to a frameshift (Luetteke et al., 1999). It was reported 
previously that AREG-KO mice show no alterations in growth or body weight, but fe-
male 4-week-old AREG-KO mice have less trabecular bone as compared to their WT 
control littermates (Luetteke et al., 1999, Qin et al., 2005). It has been described by 
Qin and co-workers that female 4-week-old AREG-KO mice have a reduced trabecular 
number, trabecular thickness, connectivity density and percent bone volume in the 
proximal tibia, and as a consequence an increased trabecular separation, whereas no 
differences were found in the cortical bone compartment (Qin et al., 2005). In our study, 
µ-CT analysis showed that 3-month-old female AREG-KO mice had a mildly reduced 
cortical BMD and 8-month-old female AREG-KO mice showed a minor cortical thinning 
at the femoral midshaft as compared to WT controls. However, there were no differ-
ences in the trabecular bone compartment in the distal femoral metaphysis (Jay et al., 
2015). The different results between our study and that of Qin and co-workers are 
probably due to the different age of the animals (early puberty versus sexual maturity). 
Our data indicate that the lack of AREG does not lead to major abnormalities on cortical 
and trabecular bone on non-growing, sexually mature female mice (Jay et al., 2015). 
To investigate to which extent the lack of AREG might be functionally compensated by 
other EGFR ligands in bone cells in vivo, the expression levels in osteoblasts harvested 
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from the distal femoral metaphysis of male and female 3-week-old AREG-KO, hetero-
zygous AREG+/- and WT mice were analyzed by qRT-PCR in our study. The expres-
sion levels of Btc and Epgn were decreased in osteoblasts of AREG-KO mice as com-
pared to their controls. The mRNA expression level of Ereg remained unchanged, 
whereas the levels of Egf and Hbegf were significantly increased in osteoblasts of 
AREG-KO mice as compared to their controls. A similar tendency was seen in the 
mRNA levels of Tgfa (P=0.062) (Jay et al., 2015). The increased expression levels of 
Egf, Hbegf and Tgfa in AREG-KO mice might, at least in part, be counterbalancing the 
effects of AREG deficiency and therefore explaining the only minor skeletal alterations 
in AREG-KO mice. 
In line with these findings, it was previously reported that reduced expression of one 
EGFR-ligand can alter the expression levels of the other EGFR-ligands. In EPGN de-
ficient mice, the expression of Btc was increased in testes and Egf expression was 
increased in kindney, lung and testes (Dahlhoff et al., 2013). After hepatic injury, which 
leads to increased expression of Areg, the expression of Tgfa, Egf and Btc were de-
creased as compared to baseline levels, whereas the expression of Ereg was in-
creased (Berasain and Avila, 2014, Berasain et al., 2005). 
In our study no differences in the femurs of male AREG-KO mice were found in pQCT 
analyses (unpublished data), indicating that the mild effects of AREG deficiency on 
cortical bone are sex-specific. In line with these findings, the reduction in trabecular 
bone volume in 4-week-old (pubescent) AREG-KO mice was only described in females 
(Qin et al., 2005). 
Skeletal sex-dependent differences in mice occur during puberty (3 to 8 weeks of age) 
and are characterized by a larger and stronger skeleton in male animals as compared 
to females (Callewaert et al., 2010c). The sexual hormones estrogen and testosterone 
and their receptors are involved in the development of skeletal sexual dimorphism and 
have an important impact on skeletal growth and bone homeostasis (Callewaert et al., 
2010b). The primary female sex hormone estrogen limits periosteal bone expansion 
but stimulates endosteal bone apposition in females (Callewaert et al., 2010b, 
Callewaert et al., 2010c). Estrogen can act directly on bone cells and functional estro-
gen receptors are expressed in osteoblasts, osteocytes and osteoclasts (Riggs et al., 
2002, Braidman et al., 2000, Eriksen et al., 1988, Oursler et al., 1991, Tomkinson et 
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al., 1998). In vitro studies showed that estrogen can increase proliferation and differ-
entiation of mouse bone marrow derived osteoblastic-like cells, and it can increase 
osteoclast apoptosis (Qu et al., 1998, Hughes et al., 1996). Estrogen deficiency leads 
to an increased bone resorption and is a main reason for postmenopausal osteoporo-
sis in elderly women (Riggs et al., 2002, Manolagas, 2000). In addition to the actions 
of sex steroid hormones on bone, it is well established that growth hormone (GH, so-
matotropin) and IGF1 play a critical role in pubertal bone growth and in the develop-
ment of skeletal sexual dimorphism. Estrogen can interact with IGF1 by increasing the 
expression of Gh and can therefore, in addition to its direct action on bone cells, indi-
rectly modulate skeletal growth (Callewaert et al., 2010b, Callewaert et al., 2010c, 
Mauras et al., 1996). In addition to the effects of sex on bone, it has been established 
that bone tissue has in its turn an influence on murine (and human) fertility, as the 
osteoblast specific hormone osteocalcin can modulate testosterone synthesis 
(Karsenty and Oury, 2014). Furthermore, estrogen can increase the expression of Areg 
and Erbb2 in MCF-7 human breast carcinoma cells, indicating that Areg is an estrogen 
target gene in vitro (Vendrell et al., 2004). Most recently, Areg has been identified as 
a key target gene of estrogen receptor positive breast cancer cells (Peterson et al., 
2015). 
As in mice, the human male skeleton is larger and stronger than the female skeleton. 
Moreover, men do not experience menopause and therefore lose less bone during 
aging (Callewaert et al., 2010a). 
During menopause, the dropping levels of ovarian estrogen lead to accelerated bone 
loss and can cause postmenopausal osteoporosis (Cauley, 2014). Estrogen deficiency 
leads to an increased secretion of several bone-resorbing cytokines, such as IL1, IL6, 
tumor necrosis factor α (TNF), macrophage colony-stimulating factor (MCSF), and 
granulocyte-macrophage colony-stimulating factor (GMCSF) (Pacifici, 1996, Tella and 
Gallagher, 2014, Khosla et al., 2012). Loss of estrogen also leads to an increased NF-
κB activity in osteoblasts, resulting in a suppressed osteoblast activity and inhibited 
bone formation (Chang et al., 2009, Khosla et al., 2012). 
There are two major approaches to treat osteoporosis: to prevent bone loss using anti 
resorptive agents (e.g. bisphosphonates, denosumab) and to stimulate bone formation 
with bone anabolic agents (e.g. strontium ranelate, teriparatide) (Tella and Gallagher, 
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2014). Bisphosphonates decrease bone turnover by inhibiting osteoclast formation. 
Denosumab is a monoclonal antibody, which specifically binds RANKL, hence sup-
pressing osteoclast formation by inhibiting the binding of RANKL to its receptor RANK 
(Tella and Gallagher, 2014). Strontium renalate is, besides teriparatide, one of the few 
bone anabolic agents used in osteoporosis treatment. It stimulates bone formation by 
increasing osteoblast proliferation, but treatment with strontium renalate is contraindi-
cated in patients with cardiovascular diseases (Canalis et al., 1996, Marie et al., 2001, 
Reginster et al., 2015). Teriparatide contains recombinant human PTH (1-34) and can 
increase bone formation when injected intermittently (Poole and Reeve, 2005). Daily 
treatment with teriparatide rapidly increases bone mass and even weekly injections 
can lead to a bone anabolic effect (Sugiyama et al., 2015). 
However, the detailed mechanisms behind the bone anabolic actions of intermittent 
PTH treatment have not yet been fully understood. Several signaling pathways have 
been identified to play a role in mediating the bone anabolic effect of intermittent PTH 
treatment (Schneider et al., 2012), e.g. IGF1 (Miyakoshi et al., 2001), c-fos (Demiralp 
et al., 2002), IL18 (Raggatt et al., 2008), ß-arrestin 2 (Bouxsein et al., 2005), sclerostin 
(Kramer et al., 2010a) and the osteoclast regulating factor MCP1 (Tamasi et al., 2013). 
The bone anabolic effect of intermittent PTH was blunted in 5-week-old IGF1 deficient 
mice (Miyakoshi et al., 2001), in 4-day-old c-fos deficient mice (Demiralp et al., 2002), 
in 7- to 8-week old IL18 deficient mice (Raggatt et al., 2008), in 4- and 6- month-old 
MCP1 deficient mice (in females to a lesser extent than in males) (Tamasi et al., 2013) 
and in 8-week-old sclerostin deficient male mice and in 6-month-old sclerostin overex-
pressing mice (Kramer et al., 2010b). In 13-week-old female and in 12-week-old male 
ß-arrestin 2 deficient mice the bone anabolic effect of intermittent PTH was altered and 
varied according to the sex (Bouxsein et al., 2005, Ferrari et al., 2005). 
The EGFR ligand Areg was identified as a PTH target gene in vitro and in vivo (Qin et 
al., 2005). In rat UMR 106-01 osteoblastic cells Areg expression was increased more 
than 2-fold 4h and 12h after treatment with rat PTH (1-34) (Qin et al., 2003). In rat 
calvarial osteoblasts, administration of rat PTH (1-34) increased the expression of Areg 
with the highest induction (23-fold) on day 14 (mineralization phase) and the lowest (5-
fold) at day 6 (proliferative phase). The strongest induction was at 1h after administra-
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tion in all three phases of proliferation, differentiation and mineralization, while the ba-
sal Areg expression levels did not change (Qin et al., 2005). In mouse MC3T3 cells 
Areg expression was also increased after PTH treatment (Qin et al., 2005). In vivo, 
intermittent treatment of 4-week-old male Sprague-Dawley rats with human PTH (1-
38) increased Areg expression in the distal femoral metaphysis 12-fold after 1h and 2-
fold after 4h (Qin et al., 2005). Areg expression was also stimulated by other osteo-
tropic hormones, such as prostaglandin E2 and 1,25 dihydroxyvitamin D3, in rat primary 
osteoblastic cells. Treatment of rat primary osteoblastic cells with prostaglandin E2 in-
creased Areg expression with a peak (13-fold) after 1h. Administration of 1,25 dihy-
droxyvitamin D3 to rat primary osteoblastic cells increased Areg expression with a peak 
(24-fold) after 12h, but was lower at 1h (3-fold) and 4h (2-fold) (Qin et al., 2005). Pre-
viously, other in vitro studies showed that Areg is also a 1,25 dihydroxyvitamin D3 target 
gene in cells derived from a human squamous cell carcinoma and in human breast 
cancer cell lines (Akutsu et al., 2001). 
Furthermore, in vitro studies showed that AREG stimulates proliferation and prevents 
differentiation and mineralization of rat calvarial osteoblasts (Qin et al., 2005). Addition 
of AREG to the medium of rat calvarial preosteoblastic cells increased their prolifera-
tion even in low concentrations (5ng/ml). Inhibition of the EGFR blocked this prolifera-
tive effect of AREG, indicating that this effect is mediated via EGFR signaling. The 
presence of ß-glycerolphosphate and ascorbic acid usually induces differentiation and 
mineralization of calvarial osteoblasts, which start to build bone nodules (Qin et al., 
2005). Administration of AREG to the medium either from day 1 or day 7 to day 20 
completely inhibited differentiation, as there was no formation of bone nodules. Analy-
sis of RNA harvested from these day 20 cultures showed an increase in the expression 
of several bone markers, such as Mmp13, alkaline phosphatase, osteocalcin and os-
teonectin in AREG-treated cells as compared to untreated cells (Qin et al., 2005). 
AREG also stimulated the phosphorylation of AKT and ERK, two major downstream 
signaling pathways activated by the EGFR, and increased the expression of c-jun and 
c-fos, whose expression can be activated by phosphorylated ERK (Qin et al., 2005). 
AREG was also identified as a chemotactic factor for mesenchymal progenitors (Zhu 
et al., 2012). PTH treatment leads to release of AREG from osteoblastic cells, which 
promotes the migration of mesenchymal progenitors in vitro via AKT and p38MAPK 
pathways (Zhu et al., 2012). In the same study it was shown that the bone anabolic 
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effect was blunted in EGFRwa5/flox Col 3.6-Cre mice, indicating that the bone anabolic 
properties of intermittent PTH require EGFR signaling. However, the bone anabolic 
effect was fully maintained in heterozygous Wa5 mice, most likely due to residual 
EGFR activity in these animals (Schneider et al., 2012). 
AREG seems to be the major EGFR ligand mediating the bone anabolic effect of PTH 
(Schneider et al., 2009b). To investigate the role of AREG in mediating the bone ana-
bolic actions of PTH, we treated 3-month-old female AREG-KO and WT mice intermit-
tently with PTH or vehicle (physiological saline) five times a week over a period of four 
weeks and analyzed their bone phenotype in detail. 
Surprisingly, the bone anabolic effect of PTH was fully maintained in female AREG-
KO mice in our study (Jay et al., 2015). In the femoral midshaft, microground histolog-
ical sections revealed a strong increase in the cortical thickness in PTH-treated AREG-
KO and WT mice as compared to their saline-treated controls. µ-CT analysis confirmed 
a higher BMD and cortical thickness in the femoral midshaft of the PTH-treated mice 
(Jay et al., 2015). There were no differences in the PTH-mediated increase of cortical 
BMD and cortical thickness between AREG-KO and WT mice. In line with the previous 
findings in 3- and 8-month-old AREG-KO mice, there was a small reduction in the cor-
tical BMD and cortical thickness in the vehicle-treated AREG-KO mice as compared to 
their WT controls (Jay et al., 2015). PTH treatment profoundly increased the amount 
of newly formed periosteal and endocortical bone. Measurement of the periosteal and 
endocortical mineral apposition rate (MAR) showed a marked increase in the bone 
formation over the four weeks of experiment in both WT and AREG-KO mice. 
In the distal femoral metaphysis intermittent PTH treatment led to an increase in BMD, 
trabecular thickness and bone formation rate (BFR) in both AREG-KO and WT mice 
as compared to their saline-treated controls (Jay et al., 2015). Consistent with the pre-
vious results in 3- and 8-month-old mice, no differences were observed in the trabec-
ular bone compartment between vehicle-treated AREG-KO and WT mice. 
The number of osteoclasts per bone perimeter was lower in PTH-treated AREG-KO 
mice as compared to PTH-treated WT mice. It is known that intermittent PTH treatment 
leads to higher expression levels of Rankl, resulting in an increased osteoclast for-
mation and therefore bone resorption, most likely to sustain the balance between bone 
formation and bone resorption (Li et al., 2007a). Osteoclasts do not express functional 
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EGFR, but it was shown by Zhu and co-workers that EGFR ligands can indirectly in-
crease osteoclast recruitment by modulating the expression of Mcp1 and Opg (Zhu et 
al., 2007). EGFR ligands can stimulate the expression of Mcp1 in osteoblasts, resulting 
in an increased osteoclast formation (Zhu et al., 2007). Additionally, it has to be men-
tioned that Rankl, whose expression is increased by intermittent PTH treatment, also 
stimulates Mcp1 expression and can therefore not only directly, but also indirectly pro-
mote osteoclastogenesis (Kim et al., 2005, Li et al., 2007a). EGFR ligands seem to 
have no apparent effect on Rankl expression in osteoblastic cells (Kim et al., 2005). 
Furthermore, EGFR ligands can inhibit the expression of Opg and further increase os-
teoclast formation (Zhu et al., 2007). Normally, OPG acts as a decoy receptor for 
RANKL and blocks its binding to RANK, leading to a reduced osteoclast formation 
(Boyle et al., 2003). Moreover, it has been reported that EGFR-KO mice have delayed 
osteoclast recruitment into the hypertrophic cartilage, and a reduced osteoclast num-
ber was observed at the border to the bone marrow space in TGFA-KO mice and in 
mice with a reduced EGFR activity specifically in chondrocytes (Usmani et al., 2012, 
Wang et al., 2004, Zhang et al., 2013). In line with these findings, our data indicate that 
the absence of AREG leads to a reduced recruitment of osteoclasts and therefore to a 
reduced bone resorption under PTH-mediated bone anabolic conditions, while the BFR 
was similar to that of PTH-treated WT mice. However, this reduction in bone resorption 
did not translate into a stronger bone anabolic effect in PTH-treated AREG-KO mice in 
comparison to PTH-treated WT mice (Jay et al., 2015). 
To evaluate the effects of intermittent PTH treatment at the whole body level, we meas-
ured the serum levels of osteocalcin. Osteocalcin is a non-collagenous protein prefer-
entially expressed by mature, mineralized osteoblasts, and used as a marker for bone 
formation, since it directly reflects the level of osteoblast formation and activity (Neve 
et al., 2013, Chapurlat and Confavreux, 2016). In vitro studies showed that PTH can 
promote osteocalcin transcription in osteoblastic-like cells (Yu and Chandrasekhar, 
1997). Osteocalcin is also released by osteoclasts in vitro, and administration of PTH 
increases the levels of osteocalcin in osteoclasts (Ivaska et al., 2004). The levels of 
serum osteocalcin were similarly increased in the PTH-treated WT and AREG-KO mice 
as compared to their vehicle-treated controls. This finding further indicates that the lack 
of AREG does not impair the bone anabolic effect of intermittent PTH treatment, not 
only at the femur but possibly also on the whole body level (Jay et al., 2015). 
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The level of urinary collagen crosslink deoxypyridinoline (DPD) was unchanged be-
tween the groups. Urinary DPD is a product of collagen degradation and is used as a 
marker for bone resorption (Vesper et al., 2003). However, a possible effect of inter-
mittent PTH treatment on bone resorption could not be assessed with this marker. 
 
Previously it was shown by Zhang and co-workers that the bone anabolic action of 
intermittent PTH was blunted in in EGFRwa5/flox Col 3.6-Cre mice, indicating that this 
effect requires signaling via the EGFR (Zhu et al., 2012). AREG was assumed to be 
the most important ligand of the EGFR in bone and was identified as a PTH target 
gene in vitro and in vivo (Qin et al., 2003, Qin et al., 2005). Surprisingly, the bone 
anabolic response was fully maintained in AREG-KO mice. It is likely that other path-
ways and growth factors might compensate the lack of AREG. Microarray analysis 
identified Tgfa as a PTH-regulated gene (Qin et al., 2003). In UMR 106-01 osteoblastic 
cells Tgfa expression was increased 2.5-fold 4h after PTH treatment. The expression 
of the proto-oncogene c-fos, whose transcription can be activated via EGFR signaling, 
was also found to be upregulated in this study (7-fold after 4h, 2.5-fold after 12h) (Qin 
et al., 2003, Schneider et al., 2009b). It is possible that in absence of AREG, TGFA or 
other EGFR ligands can mediate the bone anabolic effect of PTH via the EGFR. 
Several studies showed that EGFR signaling leads to an anabolic effect in bone. 3-
month-old EGFRwa5/flox Col 3.6-Cre mice have shorter femurs and a significantly re-
duced total BMD, trabecular BMD and cortical thickness (Zhang et al., 2011b). Vice 
versa, mice with a constitutively activation and increased signaling of the EGFR have 
a higher trabecular BMD in both sexes, and a higher total BMD in females (Fitch et al., 
2003, Zhang et al., 2011b). However, 6-month-old female Dsk5 mice do not exhibit a 
bone phenotype, while there is still a profound increase in bone volume in age-matched 
male Dsk5 mice, indicating that sex-specific factors, e.g. estrogen, might influence the 
effects of EGFR signaling in bone (Zhang et al., 2011b). In line with the findings in 
osteoblast-specific EGFR-KO mice, 3-month-old heterozygous Wa5 mice in a C57BL/6 
background have a reduced total BMD in femurs and lumbar vertebral bodies 
(Schneider et al., 2012). In a different genetic background (129S1/SvImJ) 1- and 3-
month-old heterozygous Wa5 mice did not develop a bone phenotype (Zhang et al., 
2011b). Such phenotypic variations depending on the genetic background have been 
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reported earlier in total EGFR-KO mice (Sibilia and Wagner, 1995, Threadgill et al., 
1995). 
While lack of AREG leads to a reduced trabecular bone mass in 4-week-old female 
mice and to slightly reduced BMD and minor cortical thinning in sexually mature female 
mice, Areg overexpression leads to a transient increase in the trabecular bone mass 
(Qin et al., 2005, Vaidya et al., 2015, Jay et al., 2015). Mice with an osteoblast-specific 
overexpression of Areg under the control of the 2.3kb collagen α1 promoter (COL1-
AREG) showed an increased trabecular BMD in the distal femoral metaphysis at 4, 8, 
and 10 weeks of age as compared to WT controls (Vaidya et al., 2015). However, the 
bone phenotype was transient and completely disappeared in 5- and 18-month-old 
mice. No differences were found in the femoral midshaft and in the lumbar vertebrae 
between COL1-AREG and WT mice, indicating that the effects of Areg overexpression 
are site-specific and growth-related. The number of osteoclasts was significantly lower 
in 4-week-old COL1-AREG mice, while the trabecular BFR remained unchanged, indi-
cating that the transient increase in trabecular BMD is due to a reduced bone resorp-
tion (Vaidya et al., 2015). These data demonstrate that EGFR ligands can not only 
stimulate osteoclastogenesis, but that an increased EGFR activity in consequence of 
AREG overabundance can also decrease osteoclast formation (Zhu et al., 2007, 
Vaidya et al., 2015). Furthermore, in vitro studies with mouse calvarial osteoblasts 
showed that Areg overexpression did not change osteoblast differentiation or prolifer-
ation (Vaidya et al., 2015). 
In conclusion, our data suggest that AREG is dispensable for the bone anabolic actions 
of intermittent PTH treatment. AREG plays only a minor role in bone development, and 
lack of AREG results in a reduced cortical thickness and cortical BMD in sexually ma-
ture female mice (Jay et al., 2015). 
Analysis of the expression levels of the other EGFR ligands in AREG-KO osteoblasts 
revealed an increased expression of Egf and Hbegf and a similar trend was seen for 
Tgfa. The latter is of particular interest, because Tgfa was previously reported to be a 
PTH target gene in osteoblasts. Microarray analysis showed that Tgfa expression was 
increased in rat UMR 106-01 osteoblastic cells after PTH treatment (Qin et al., 2003). 
Both Hbegf and Tgfa have been previously reported to be PTH-regulated target genes 
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in rat UMR 106-01 osteoblastic cells (Qin et al., 2005). Future analysis of the expres-
sion levels of the other EGFR ligands in AREG deficient osteoblasts under PTH-medi-
ated bone anabolic conditions will help to gain a greater knowledge about the ability of 
the other ligands to compensate the lack of AREG. In vivo studies, assessing the role 
of TGFA alone and in combination with AREG, will help to gain greater insight in the 
role of EGFR signaling in mediating the bone anabolic actions of intermittent PTH treat-
ment. 
To further understand the underlying mechanisms of the bone anabolic effect of PTH, 
future work needs to assess the role of EGFR signaling in bone in combination with 
the closely related ERBB2 receptor, which is the preferred heterodimerization partner 
of EGFR and the EGFR family member with the highest expression in bone cells (Citri 
and Yarden, 2006, Genetos et al., 2010, Jay et al., 2015). 
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6 Summary 
 
Parathyroid hormone (PTH) is a key regulator of bone remodeling and calcium home-
ostasis. It is well established that PTH, in contrast to its classical bone catabolic ac-
tions, can also act as a bone anabolic agent when administered intermittently (Tam et 
al., 1982, Poole and Reeve, 2005). 
In recent years, numerous signaling pathways and molecules have been proposed as 
mediators of this paradoxical action. However, the detailed mechanisms remain largely 
unknown. Amphiregulin (AREG), a ligand of the epidermal growth factor receptor 
(EGFR) has been identified as a PTH target gene in vitro and in vivo, and there is 
accumulating evidence that the bone anabolic actions of PTH might be, at least in part, 
mediated via AREG-EGFR-signaling (Schneider et al., 2009b, Qin et al., 2005). Areg 
expression was highly increased in UMR 106-01 osteoblastic cells, primary rat calvarial 
osteoblasts, mouse MC3T3 cells and in the femoral metaphysis of young male rats 
after PTH treatment (Qin et al., 2003, Qin et al., 2005). Furthermore, AREG stimulates 
proliferation and inhibits differentiation and mineralization of osteoblasts and Areg ex-
pression is also increased by other osteotropic hormones, such as prostaglandin E2 
and 1,25-dihydroxyvitamin D3 (Qin et al., 2005). Mice lacking AREG show no altera-
tions in growth but they have been reported to have less trabecular bone as compared 
to controls (Qin et al., 2005, Luetteke et al., 1999). Vice versa, mice overexpressing 
Areg specifically in osteoblasts showed a transient increase of bone mass in the tra-
becular bone compartment (Vaidya et al., 2015). Taken together, these data indicate 
that AREG seems to be the major EGFR-ligand in mediating the bone anabolic prop-
erties of intermittent PTH. 
To clarify to which extent AREG is required for the bone anabolic actions of PTH in 
vivo, we treated 3-month-old female global AREG knockout (AREG-KO) mice and con-
trols with 80µg/kg PTH (1-34) or vehicle (physiological saline) five times per week over 
four weeks and analyzed their bone phenotype via bone histomorphometry. Addition-
ally, we analyzed the levels of serum osteocalcin, a marker for bone formation, and 
urinary deoxypyridinoline, a marker for bone resorption. 
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Intermittent PTH treatment of AREG-KO mice led to an increased bone formation of 
trabecular and cortical bone, which was comparable to the effect in control animals. 
Hence, the bone anabolic effect was fully maintained in AREG-KO mice. Surprisingly, 
the number of osteoclasts per bone perimeter was decreased in PTH-treated AREG-
KO mice relative to their respective wildtype controls, indicating that lack of AREG 
leads to a reduced osteoclastogenesis under PTH-mediated bone anabolic conditions. 
However, this reduction did not translate into a stronger bone anabolic effect in AREG-
KO mice. The levels of serum osteocalcin were increased in both PTH-treated groups 
as compared to their vehicle-treated controls, suggesting that PTH might lead to an 
increased bone anabolism at the whole body level in both wildtype and AREG-KO 
mice. The urinary levels of deoxypyridinoline remained unchanged between the 
groups, indicating that the effect of PTH on bone resorption could not be assessed with 
this marker. 
In conclusion, our data indicate that AREG is dispensable for the bone anabolic ef-
fect of intermittent PTH, at least in 3-month-old female mice. 
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7 Zusammenfassung 
 
Parathormon (PTH) ist ein Hauptregulator des Knochenstoffwechsels und der Calci-
umhomöostase. Es ist allgemein bekannt, dass PTH im Gegensatz zu seiner klassi-
schen knochenkatabolen Eigenschaft auch knochenanabol wirken kann, wenn es in-
termittierend verabreicht wird (Tam et al., 1982, Poole and Reeve, 2005). 
In den letzten Jahren wurden von zahlreichen Signalwegen und Moleküle vermutet, 
dass sie diesen paradoxen Effekt vermitteln. Die genauen Mechanismen sind jedoch 
immer noch weitestgehend unbekannt. Amphiregulin (AREG), ein Ligand des Epider-
mal Growth Factor Receptors (EGFR), wurde in vitro und in vivo als PTH-reguliertes 
Gen identifiziert, und es gibt zunehmend Hinweise darauf, dass die knochenanabole 
Wirkung von PTH zumindest teilweise über den AREG-EGFR-Signalweg vermittelt 
sein könnte (Schneider et al., 2009b, Qin et al., 2005). Die Expression von Areg war 
in UMR 106-01 osteoblasten-ähnlichen Zellen, in primären Osteoblasten aus Ratten-
Calvarien, in Maus-MC3T3 Zellen und in der Metaphyse des Femurs junger männli-
cher Ratten nach PTH-Behandlung stark erhöht (Qin et al., 2003, Qin et al., 2005). 
Zudem stimuliert AREG die Proliferation von Osteoblasten, während es ihre Differen-
zierung und Mineralisation hemmt. Auch andere osteotrope Hormone, wie Prostaglan-
din E2 und 1,25-Dihydroxyvitamin D3, erhöhen die Expression von Areg (Qin et al., 
2005). Mäuse, denen AREG fehlt, zeigen kein verändertes Wachstum, aber sie haben 
weniger trabekulären Knochen im Vergleich zu Kontrolltieren (Qin et al., 2005, 
Luetteke et al., 1999). Umgekehrt zeigen Mäuse mit osteoblasten-spezifischer Über-
expression von Areg einen transienten Anstieg der trabekulären Knochenmasse 
(Vaidya et al., 2015). All diese Daten weisen darauf hin, dass AREG vermutlich der 
wichtigste Ligand des EGFR ist, der die knochenanabolen Eigenschaften von intermit-
tierend verabreichtem PTH vermittelt. 
Um zu klären, inwieweit AREG für die knochenanabole Wirkung von PTH in vivo be-
nötigt wird, wurden 3 Monate alte weibliche ubiquitäre AREG-Knockout Mäuse (AREG-
KO) und Kontrolltiere mit 80µg/kg PTH (1-34) oder Trägersubstanz (physiologische 
Kochsalzlösung) fünfmal die Woche für vier Wochen behandelt, und der Knochenphä-
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notyp histomorphometrisch ausgewertet. Zusätzlich wurde die Osteocalcin-Konzent-
ration im Serum, ein Marker für die Knochenformation, und die Deoxypyridinoline-Kon-
zentration im Urin, ein Marker für die Knochenresorption, gemessen. 
Die intermittierende Behandlung mit PTH führte zu einer erhöhten kortikalen und tra-
bekulären Knochenneubildung in AREG-KO Mäusen, die mit der in Kontrollmäusen 
vergleichbar war. Der knochenanabole Effekt war also in AREG-KO Mäusen in vollem 
Umfang erhalten. Überraschenderweise war die Anzahl der Osteoklasten in Relation 
zum Knochenumfang in den mit PTH behandelten AREG-KO Mäusen niedriger als in 
der entsprechenden Wildtyp-Kontrollgruppe. Dies lässt darauf schließen, dass in Ab-
wesenheit von AREG unter PTH-vermittelten knochenanabolen Bedingungen weniger 
Osteoklasten gebildet werden. Diese Reduktion führte jedoch nicht zu einem stärkeren 
knochenanabolen Effekt in AREG-KO Mäusen. In beiden mit PTH behandelten Grup-
pen war im Vergleich zu den mit Trägersubstanz behandelten Kontrollgruppen ein An-
stieg an Osteocalcin im Serum feststellbar. Dies weist darauf hin, dass PTH sowohl 
bei AREG-KO Mäusen als auch bei Kontrolltieren im gesamten Körper knochenanabol 
wirken könnte. Die im Urin gemessenen Werte von Deoxypyridinoline unterschieden 
sich nicht zwischen den Gruppen, was vermuten lässt, dass der Einfluss der PTH-
Behandlung auf die Knochenresorption mit diesem Marker nicht erfasst werden 
konnte. 
Zusammengefasst deuten unsere Daten darauf hin, dass AREG für den knochenana-
bolen Effekt, zumindest in 3 Monate alten weiblichen Mäusen, nicht benötigt wird. 
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